tag:blogger.com,1999:blog-64692386891840498402024-03-13T04:51:25.159-07:00News from the EACPTEACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.comBlogger121125tag:blogger.com,1999:blog-6469238689184049840.post-89961499194670243012022-04-01T02:57:00.005-07:002022-04-01T03:31:59.795-07:00Reinforced role for European Medicines Agency in crisis preparedness and management for medicinal products and medical devices<div class="separator" style="clear: both; text-align: center;"><span style="font-size: small;"><span style="font-family: arial;"><span><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhLyI0U1ZeRYVSEdNrWv4WsFnNFtpiaRiS0pw7zhZDYRESgmLoH03kZwV-EEEXntVIc0Rz3CZMU45fVwOu4dyOBr5Y_jaaeJgYR7nTeyAw-dTZG7koEiUctpF4P3AIc6NcXL8gA8peqCO39yf7ur9kmcH0h6qujVTdOoUiFfD3Agk-yMg8rVT-1MvHb/s742/Screenshot%202022-04-01%20at%2010.54.34.png" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="182" data-original-width="742" height="78" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhLyI0U1ZeRYVSEdNrWv4WsFnNFtpiaRiS0pw7zhZDYRESgmLoH03kZwV-EEEXntVIc0Rz3CZMU45fVwOu4dyOBr5Y_jaaeJgYR7nTeyAw-dTZG7koEiUctpF4P3AIc6NcXL8gA8peqCO39yf7ur9kmcH0h6qujVTdOoUiFfD3Agk-yMg8rVT-1MvHb/s320/Screenshot%202022-04-01%20at%2010.54.34.png" width="320" /></a></span></span></span></div><span style="font-size: small;"><span style="font-family: arial;"><span>1.4.22: The European Medicines Agency <a href="https://www.ema.europa.eu/en/events/multistakeholder-workshop-emas-extended-mandate" target="_blank">(EMA) is today holding a workshop</a> to inform stakeholders of <span style="color: black; mso-themecolor: text1;">the regulation reinforcing the EMA’s role </span>in
crisis preparedness and management for medicines and medical devices [<a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022R0123">REGULATION
(EU) 2022/123 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL</a>].<span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;"> </span></span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">The new regulation was triggered largely in
response to the COVID-19 pandemic ie a civil crisis to aim for better readiness
to anticipate and respond to public health emergencies. It is clearly also relevant
to shortages arising from conflicts such as related to Russia’s war against the
Ukraine and the resulting mass migration. </span></span></span></span>
</p><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">This new Regulation [EU – 2020/123] of 25<sup>th</sup>
January 2022 was determined to be effective from the date of its publication in
the Official Journal of the European Union – 31<sup>st</sup> January 2022 and
in practice applicable from 1<sup>st</sup> March 2022 for the monitoring and
mitigation of shortages of critical medicinal products. The EMA is already
starting preparatory work with the aim of delivery the European Shortages
Monitoring Platform in early 2025.</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Success will depend on clear allocation of tasks
and responsibilities. High level aims are improved, co-ordinated ways to identify
shortages – including mapping surges in demand, streamline processes, remove barriers
and enhance preparedness so that when issues arise the EMA and its partner agencies
can react in the quickest way possible, within the spirit of the Charter of
Fundamental Rights of the European Union that the Union is to “ensure a high
level of human health protection in the definition and implementation of all
Union policies and activities.” <br /></span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">The Regulation covers the following topics:</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><ul type="disc"><li class="MsoNormal" style="mso-list: l0 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Monitoring and mitigating shortages of
medicines and devices</span></span></span></span></li><li class="MsoNormal" style="mso-list: l0 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Addressing public health emergencies through
the Emergency Task Force (ETF)</span></span></span></span></li><li class="MsoNormal" style="mso-list: l0 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Coordinating expert panels on high-risk
medical devices and in vitro diagnostics</span></span></span></span></li></ul><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">The event provided an opportunity for the
public and stakeholders to inform EMA of their needs, expectations and to discuss
opportunities for further engagement with the agency.<br /></span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">Key milestones for the EMA include:</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">1<sup>st</sup> March 2022 – start of development of
systems re shortages of critical medicines including enhanced IT platforms</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">2<sup>nd</sup> August 2022 – establishing a list of
the main therapeutic groups for hospital care</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">2<sup>nd</sup> September 2022 – registration of
i-SPOCs (Single Points of Contact) from Marketing Authorisation Holders</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">2<sup>nd</sup> February 2023 – development of
systems re shortages of medical devices/in-vitro diagnostics</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">2<sup>nd</sup> February 2025 – European Shortages
Monitoring Platform “goes live”<br /><br /></span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB;">The following are brief notes on the background and
high level actions defined within the new <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022R0123">Regulation</a>.
</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial;"><span><span style="display: none; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-GB; mso-hide: all;"> </span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span>The
COVID-19 pandemic has highlighted the interconnectedness of human and animal
ecosystems with regard to risks to health including two-thirds of new diseases
and most pandemics from influenza to COVID-19. New risks include effects of changes
in land use, new agricultural methods, wildlife trafficking and changes in food
consumption.</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span>“…
as stated in Regulation (EU) 2021/522 of the European Parliament and of the
Council (4), ‘human health is connected to animal health and to the
environment and … actions to tackle threats to health must take into account
those three dimensions’”.</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span>Experience
of the COVID-19 pandemic has highlighted lack of readiness <span style="mso-spacerun: yes;"> </span>of the European Union and its Member States to
addressing major public health emergencies. The EU has been “severely impeded
by the absence of a clearly defined legal framework for managing its response
to pandemics and by the limited mandates and resources of its health agencies,
as well as by the limited degree of Union and Member States preparedness for
public health emergencies that impact a majority of the Member States.”</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span>“Shortages
of medicinal products and medical devices have different and complex root
causes which need to be further mapped, understood and analysed together with
the different stakeholders in order to be comprehensively addressed. A better
understanding of those shortages should include identification of
vulnerabilities in the supply chain. In the specific case of the COVID-19
pandemic, the shortage of treatments for the disease had a variety of causes,
ranging from production difficulties in third countries to logistical or
production difficulties within the Union, where the shortage of vaccines was
due to inadequate manufacturing capacity.”</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span>Disruptions
to supply chains for medicinal products and medical devices include “national
export restrictions and bans, border closures impeding the free movement of
such goods, uncertainty related to the supply for and demand of such goods in
the context of the COVID-19 pandemic, and the lack of production in the Union
of certain medicinal products or active substances…”.</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span>Further
challenges include “…increased risk of exposure to falsified medicinal
products, medication errors, adverse effects resulting from the substitution of
unavailable medicinal products with alternative ones, significant psychological
distress for patients and increased costs for healthcare systems. … Member
States competing with each other when they respond to the legitimate needs of
their citizens, thereby contributing to uncoordinated actions at national
level, such as national hoarding and stockpiling.”</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span>“In
order to facilitate the prevention, monitoring and reporting of shortages of
medicinal products, the Agency should set up an information technology (IT)
platform, to be known as the European shortages monitoring platform (‘ESMP’),
that is capable of processing information on the supply of and demand for
critical medicinal products during public health emergencies or major events
and, outside of those situations, to allow for reporting on shortages of
medicinal products that are likely to lead to public health emergencies or
major events.” </span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><b><span>Medicine
Shortages Steering Group – MSSG</span></b></span><span><span><br />This
executive steering group is to be established within the Agency to ensure robust
responses to major public health events and coordinate urgent actions within
the Union.</span></span><br /><span><span>The MSSG is to establish lists of critical medicinal products (CMPs), to ensure
monitoring of CMPs and provide advice and recommendations on the actions to
safeguard the quality, safety and efficacy and supply of CMPs.</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><b><span>Emergency
Task Force – ETF</span></b><span>
<br />
This new ETF is to provide advice on scientific questions related to the
development of treatments and vaccines and on clinical trial protocols free of
charge to entities involved in their development, such as marketing
authorisation holders, clinical trial sponsors, public health bodies, and
academia.</span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><b><span>Medical
Device Shortages Steering Group – MDSSG</span></b></span><span><span><br />This
new Steering Group is to coordinate urgent actions within the Union in relation
to the management of supply and demand issues of medical devices, and to
establish a list of critical medical devices in the case of a public health
emergency.</span></span><span>
</span></span></span></p><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><b><span>Robust
transparency measures and standards</span></b><span> are needed regarding the EMA’ Agency’s regulatory
activities in relation to medicinal products and medical devices relevant to this
Regulation. </span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><b><span>European
database on medical devices (Eudamed)</span></b><span><br />
Rapid access to and exchanges of health data, including real world data will be
needed and should be part of the interoperable European Health Data Space. Provision
should be made for setting up and managing new IT infrastructures and their
synergy with other existing IT systems and IT systems under development,
including Eudamed and for <b>enhanced protection of data infrastructure from possible
cyber attacks.</b> </span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><b><span>Cooperation
with European Centre for Disease Prevention and Control (‘ECDC’)</span></b><span> During public health
emergencies or major events, the Agency should ensure cooperation with the ECDC
including the sharing of data, regular communication at an executive level e.g.
re meetings of the ETF, the MSSG and the MDSSG.</span></span></span></span></p><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span><b>Donald Singer<br />EACPT Delegate<br /> EMA Healthcare Professionals Working Party</b><br /></span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><br /></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoPlainText"><span style="font-size: small;"><span style="font-family: arial;"><span><span> </span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p class="MsoNormal"><span style="font-size: small;"><span style="font-family: arial;"><span><span> </span></span></span></span></p><span style="font-size: small;"><span style="font-family: arial;"><span>
</span></span></span><p><span style="font-size: small;"><span style="font-family: arial;"><span><style>@font-face
{font-family:Helvetica;
panose-1:0 0 0 0 0 0 0 0 0 0;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536858881 -805275557 9 0 511 0;}@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;
mso-font-charset:77;
mso-generic-font-family:decorative;
mso-font-pitch:variable;
mso-font-signature:3 0 0 0 -2147483647 0;}@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:roman;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073732485 9 0 511 0;}@font-face
{font-family:Consolas;
panose-1:2 11 6 9 2 2 4 3 2 4;
mso-font-charset:0;
mso-generic-font-family:modern;
mso-font-pitch:fixed;
mso-font-signature:-520092929 1073806591 9 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:"Calibri",sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;
mso-fareast-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-fareast-language:EN-US;}a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;
text-underline:single;}a:visited, span.MsoHyperlinkFollowed
{mso-style-noshow:yes;
mso-style-priority:99;
color:#954F72;
mso-themecolor:followedhyperlink;
text-decoration:underline;
text-underline:single;}p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
{mso-style-priority:99;
mso-style-link:"Plain Text Char";
margin:0cm;
mso-pagination:widow-orphan;
font-size:10.5pt;
font-family:Consolas;
mso-fareast-font-family:Calibri;
mso-fareast-theme-font:minor-latin;
mso-fareast-language:EN-US;}span.PlainTextChar
{mso-style-name:"Plain Text Char";
mso-style-priority:99;
mso-style-unhide:no;
mso-style-locked:yes;
mso-style-link:"Plain Text";
mso-ansi-font-size:10.5pt;
mso-bidi-font-size:10.5pt;
font-family:Consolas;
mso-ascii-font-family:Consolas;
mso-hansi-font-family:Consolas;
mso-bidi-font-family:Consolas;}.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:"Calibri",sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:Calibri;
mso-fareast-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-fareast-language:EN-US;}div.WordSection1
{page:WordSection1;}ol
{margin-bottom:0cm;}ul
{margin-bottom:0cm;}</style></span></span></span></p>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-2354826171142769142020-12-01T06:07:00.004-08:002020-12-01T06:08:36.260-08:00EMA relocation from London to Amsterdam<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">The European Medicines Agencies' Human Scientific Committees' Working Parties met in London with working parties for Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) for the last time in September 2018. These working parties have been meeting regularly in London for the last 5 years to share progress and expertise. From March 2019, the EMA will relocate to Amsterdam - its top priority business continuity for regulation and pharmacovigilance of medicinal products.</span></span><br />
<br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">A key topic discussed was risk to disruption to the supply chain for centrally authorised medicinal products. </span></span><div><br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">Reasons:</span></span><br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">- supply from the UK</span></span><br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">- companies will have to make changes to their marketing authorizations for an EU without the UK.</span></span><br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">A MAH may have to move from the UK to another country in the new EU. That may lead to a delay in production of relevant medicines.</span></span><br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">Changes at the latest by December 2020.</span></span><br />
<br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">Options – where available – include switching patients to other medicines with similar efficay and safety profiles. Additional burden of falsified medicines regulations coming at a difficult time. </span></span><br />
<span face=""Helvetica Neue", Arial, Helvetica, sans-serif"><span style="font-size: small;">Other topics included updates on electronic prescribing information, progress of the joint working parties topic group on Digital Media for Health. </span></span><br />
<br />
</div>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-59205153792205319482020-11-30T04:54:00.006-08:002020-12-01T06:05:07.374-08:00Regulatory support for development of orphan medicines: virtual workshop from the European Medicines Agency<p><span style="font-size: small;"><span style="font-family: arial;"></span></span></p><div class="separator" style="clear: both; text-align: center;"><span style="font-size: small;"><span style="font-family: arial;"><span><a href="https://1.bp.blogspot.com/-rEiRjcO0gQg/X8TrfmmtzRI/AAAAAAAAC2s/Oz6UUvSuKW0F5YvLGV_eqnLHbDs3nbjAACLcBGAsYHQ/s934/Screenshot%2B2020-11-30%2Bat%2B12.54.00.png" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="238" data-original-width="934" src="https://1.bp.blogspot.com/-rEiRjcO0gQg/X8TrfmmtzRI/AAAAAAAAC2s/Oz6UUvSuKW0F5YvLGV_eqnLHbDs3nbjAACLcBGAsYHQ/s320/Screenshot%2B2020-11-30%2Bat%2B12.54.00.png" width="320" /></a></span></span></span></div><span style="font-size: small;"><span style="font-family: arial;"><span>A live online event from the European Medicines Agency on 30 November combined short talks with Q & A sessions and was intended to encourage early and efficient interactions with regulators
by highlighting pre-marketing support in medicine development for treating rare
diseases.</span></span></span><div class="ecl-editor field field-label-hidden field-name-field-ne-body field-type-text-with-summary"><div class="ecl-field__body"><div class="ecl-editor first last"><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>The meeting aimed in particular to explain existing tools relevant to early product development strategy. </span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>These include:</span></span></span></span></p><ul><li><span style="font-size: small;"><span style="font-family: arial;"><span><span><a href="https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview" target="_self">orphan designation</a>;</span></span></span></span></li><li><span style="font-size: small;"><span style="font-family: arial;"><span><span><a href="https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance" target="_self">protocol assistance</a>;</span></span></span></span></li><li><span style="font-size: small;"><span style="font-family: arial;"><span><span>the <a href="https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines" target="_self">PRIority MEdicines (PRIME) scheme</a>.</span></span></span></span></li></ul><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>Stakeholders were given an opportunity to express their views in relation to early medicine development and regulatory interactions. <br /><br />The
workshop was targeted at small to medium enterprise medicine developers,
academia, patients, healthcare professionals and European Reference
Networks (ERNs), often at the forefront of medicine development to treat rare and neglected diseases.</span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>High level points include:</span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>There are estimated to be 6-8000 orphan conditions of which around half concern diseases with an incidence of less than 1 in 10000. <br /></span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>183 orphan medical products have been registered in the EU since 2000. ~120 of these have active orphan status for treating ~130 orphan diseases ie several have indications for treating more than one disease.</span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>Around 2 in 3 orphan products are based on conventional chemical treatments and 1 in 3 involve advanced therapeutic approaches.</span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>The EMA supports SMEs and Academia in orphan drug development through a dedicated contact point, regulatory, administrative and procedural support and engaging with EU bodies and industry stakeholders.</span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>Of the ~2000 SMEs registered with the EMA, 23% are working on orphan medical products. <br /></span></span></span></span></p><p><span style="font-size: small;"><span style="font-family: arial;"><span><span>A video recording will be available after the event on the <a href="https://www.ema.europa.eu/en/events/workshop-support-orphan-medicines-development" target="_blank">EMA website.</a><br /></span></span></span></span></p></div>
</div>
</div>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-31577315243298286402020-11-26T10:42:00.008-08:002020-12-01T06:05:48.328-08:00Raising awareness to combat antimicrobial resistance: European Antibiotic Awareness Day<p class="MsoNormal" style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; margin: 0cm 0cm 0.0001pt; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;"><span style="font-family: arial;"><span style="font-size: small;"><span style="font-family: arial;"><span style="font-size: small;"><a class="ecl-link--external" href="https://antibiotic.ecdc.europa.eu/en" target="_blank">European Antibiotic Awareness Day</a></span></span> EAAD was held on 18 November 2020 with activities taking place during that week. As in previous years, the European Medicines Agency (EMA) actively contributed to raising awareness about Antimicrobial Resistance (AMR) and how to limit it by publishing a set of infocards, developed to reinforce global cooperation to combat AMR.</span></span></p><div class="paragraphs-items paragraphs-items-field-ema-paragraph-content paragraphs-items-field-ema-paragraph-content-full paragraphs-items-full">
<div class="field field-label-hidden field-name-field-ema-paragraph-content field-type-paragraphs">
<div>
<div class="ecl-field__body">
<div class="first last">
<div class="ecl-editor field field-label-hidden field-name-field-ne-body field-type-text-with-summary">
<div class="ecl-field__body">
<div class="ecl-editor first last"><p><span style="font-family: arial;"><span style="font-size: small;">EAAD is an annual European Union initiative to raise awareness of
antimicrobial resistance as an increasing global public health threat
and to promote the prudent use of antibiotics.</span></span></p><p><span style="font-family: arial;"><span style="font-size: small;">‘Tackling antimicrobial resistance is a global challenge and a high priority for EMA and the <a class="ecl-link glossary-term" href="https://www.ema.europa.eu/en/glossary/european-medicines-regulatory-network" id="glossary-term-43201" target="_blank" title="The system for regulating medicines in Europe is based on a closely coordinated regulatory network of national competent authorities in the Member States of the European Economic Area working together with the European Medicines Agency and the European Commission.
More information can be found under 'European medicines regulatory network'.">European medicines regulatory network</a>.
We all have a role to play in addressing this challenge: regulators,
governments, companies through development of new innovative
antibiotics, but also healthcare professionals and patients by making
sure they prescribe and use antibiotics wisely and responsibly’ said
Emer Cooke, EMA’s Executive Director.</span></span></p><p><span style="font-family: arial;"><span style="font-size: small;">To mark EAAD, the EMA launched a social media campaign to highlight the importance of using antibiotics prudently.</span></span></p><p><span style="font-family: arial;"><span style="font-size: small;"><a href="https://www.ema.europa.eu/en/documents/leaflet/responsible-use-antibiotics-whats-your-role-infocards_en.pdf" target="_blank">A set of info-cards</a>
focuses on what patients, healthcare professionals, veterinarians,
health-leaders, journalists and the pharmaceutical industry in their
respective roles can do on a daily basis to make sure that these
important medicines are used wisely.</span></span></p><p><span style="font-family: arial;"><span style="font-size: small;">Antimicrobial resistance
occurs when bacteria and other microorganisms change over time and
develop resistance to medicines. As a result, antibiotics and other
antimicrobial medicines become less effective. This makes infections
harder and harder to treat. A prudent use of antibiotics helps slow the
process and ensure that treatments continue to be available to treat
common and emerging infectious diseases.</span></span></p><p><span style="font-family: arial;"><span style="font-size: small;">For more information on the EMA’s role in the global response to antimicrobial resistance, see <a class="ecl-link" href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/antimicrobial-resistance">Antimicrobial resistance</a><a href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/antimicrobial-resistance">.</a></span></span></p></div>
</div>
</div>
</div>
</div>
</div></div></div><p class="MsoNormal" style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; margin: 0cm 0cm 0.0001pt; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;"><span style="font-family: arial;"><span style="font-size: small;">You can see examples of the cards below. The full set of these<a href="https://www.ema.europa.eu/en/documents/leaflet/responsible-use-antibiotics-whats-your-role-infocards_en.pdf" target="_blank"> infocards is downloadable on this link</a>. </span></span></p><p class="MsoNormal" style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; margin: 0cm 0cm 0.0001pt; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;"><span style="font-family: arial;"><span style="font-size: small;"><br /></span></span></p><p class="MsoNormal" style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; margin: 0cm 0cm 0.0001pt; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;"><span style="font-family: arial;"></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://1.bp.blogspot.com/-lyOVprYvREo/X7_2Q0FCNJI/AAAAAAAAC1Y/YaJb5lp4ir4CEPl32DbJJXqJtvejc_7ZwCLcBGAsYHQ/s2048/Screenshot%2B2020-11-26%2Bat%2B18.27.59.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1157" data-original-width="2048" src="https://1.bp.blogspot.com/-lyOVprYvREo/X7_2Q0FCNJI/AAAAAAAAC1Y/YaJb5lp4ir4CEPl32DbJJXqJtvejc_7ZwCLcBGAsYHQ/s320/Screenshot%2B2020-11-26%2Bat%2B18.27.59.png" width="320" /></a></div><br /><div class="separator" style="clear: both; text-align: center;"><a href="https://1.bp.blogspot.com/-sGwzTcscN9w/X7_2Qo10MUI/AAAAAAAAC1U/DOIQBCSb5M8OETP-C1g74AaFCtyOdJnFACLcBGAsYHQ/s2048/Screenshot%2B2020-11-26%2Bat%2B18.28.10.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1157" data-original-width="2048" src="https://1.bp.blogspot.com/-sGwzTcscN9w/X7_2Qo10MUI/AAAAAAAAC1U/DOIQBCSb5M8OETP-C1g74AaFCtyOdJnFACLcBGAsYHQ/s320/Screenshot%2B2020-11-26%2Bat%2B18.28.10.png" width="320" /></a></div><br /><div class="separator" style="clear: both; text-align: center;"><a href="https://1.bp.blogspot.com/-E-RbJMkZmJk/X7_2RFAJknI/AAAAAAAAC1c/HCJiGJOp8CU6CrSUmNemY_BwcGkWmX8GACLcBGAsYHQ/s2048/Screenshot%2B2020-11-26%2Bat%2B18.28.14.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1157" data-original-width="2048" src="https://1.bp.blogspot.com/-E-RbJMkZmJk/X7_2RFAJknI/AAAAAAAAC1c/HCJiGJOp8CU6CrSUmNemY_BwcGkWmX8GACLcBGAsYHQ/s320/Screenshot%2B2020-11-26%2Bat%2B18.28.14.png" width="320" /></a></div><br /><div class="separator" style="clear: both; text-align: center;"><a href="https://1.bp.blogspot.com/-mbkvcCnUGgM/X7_2RnqUGmI/AAAAAAAAC1g/FDWdEZbjHdoHxeEFwIAU2QmSoljjvMW7wCLcBGAsYHQ/s2048/Screenshot%2B2020-11-26%2Bat%2B18.28.17.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1157" data-original-width="2048" src="https://1.bp.blogspot.com/-mbkvcCnUGgM/X7_2RnqUGmI/AAAAAAAAC1g/FDWdEZbjHdoHxeEFwIAU2QmSoljjvMW7wCLcBGAsYHQ/s320/Screenshot%2B2020-11-26%2Bat%2B18.28.17.png" width="320" /></a></div><br /><div class="separator" style="clear: both; text-align: center;"><a href="https://1.bp.blogspot.com/-_L1KFm1PqfU/X7_2m-qp8rI/AAAAAAAAC14/QHDDMM9PjVIFiL19CTtzHjeOaHzxHDzIACLcBGAsYHQ/s2048/Screenshot%2B2020-11-26%2Bat%2B18.28.33.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1157" data-original-width="2048" src="https://1.bp.blogspot.com/-_L1KFm1PqfU/X7_2m-qp8rI/AAAAAAAAC14/QHDDMM9PjVIFiL19CTtzHjeOaHzxHDzIACLcBGAsYHQ/s320/Screenshot%2B2020-11-26%2Bat%2B18.28.33.png" width="320" /></a></div><br /><span style="font-size: small;"><br /></span><p></p><p class="MsoNormal" style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; margin: 0cm 0cm 0.0001pt; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;"><span style="font-family: arial;"><span style="font-size: small;"> </span></span></p><p class="MsoNormal" style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; margin: 0cm 0cm 0.0001pt; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;"><span style="font-family: arial;"><span style="font-size: small;"></span></span></p><div class="separator" style="clear: both; text-align: center;"><span style="font-size: small;"><br /></span></div><span style="font-size: small;"><br /> </span><p></p>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-79967895222431206532020-11-26T10:16:00.004-08:002020-12-01T06:04:16.336-08:00European Medicines Agency to hold a public update on COVID-19 vaccines on 11 December<p style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"></p><div class="separator" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em; text-align: center;"><span style="font-family: arial;"><span style="font-size: small;"><br /></span></span></div><span style="font-family: arial;"><span style="font-size: small;"><br /><span face="Verdana, sans-serif" lang="EN"><div class="separator" style="clear: both; text-align: center;"><a href="https://1.bp.blogspot.com/-MgKjUUrt_b8/X7_w2bic4OI/AAAAAAAACzI/rt51QoyqIa06sRMzphWg-NpCLWmUTV1GACLcBGAsYHQ/s1312/Screenshot%2B2020-11-26%2Bat%2B18.15.02.png" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="974" data-original-width="1312" src="https://1.bp.blogspot.com/-MgKjUUrt_b8/X7_w2bic4OI/AAAAAAAACzI/rt51QoyqIa06sRMzphWg-NpCLWmUTV1GACLcBGAsYHQ/s320/Screenshot%2B2020-11-26%2Bat%2B18.15.02.png" width="320" /></a></div><br />EMA will organise a<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/events/public-stakeholder-meeting-development-authorisation-safe-effective-covid-19-vaccines-eu" style="color: purple; text-decoration: underline;">public meeting</a><span class="Apple-converted-space"> </span>on 11 December 2020<b><span face="Verdana, sans-serif"><span class="Apple-converted-space"> </span></span></b>to inform European citizens<b><span face="Verdana, sans-serif"><span class="Apple-converted-space"> </span></span></b>about the EU regulatory processes for the approval of COVID-19 vaccines and the Agency’s role in their development, evaluation, approval and safety monitoring.</span></span></span><p style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"><span style="font-family: arial;"><span face="Verdana, sans-serif" lang="EN" style="font-size: small;">The COVID-19 pandemic is an unprecedented global crisis, with devastating health, social and economic impact. Safe and effective vaccines for COVID-19 are urgently needed to respond to this crisis and reduce its effects.</span></span></p><p style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"><span style="font-family: arial;"><span face="Verdana, sans-serif" lang="EN" style="font-size: small;">Together with the<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/glossary/european-medicines-regulatory-network" style="color: purple; text-decoration: underline;" target="_blank" title="The system for regulating medicines in Europe is based on a closely coordinated regulatory network of national competent authorities in the Member States of the European Economic Area working together with the European Medicines Agency and the European Co"><span style="color: #004494;">European medicines regulatory network</span></a>, EMA is supporting the development of COVID-19 vaccines and has taken steps to speed up the evaluation processes for these vaccines. The Agency and its partners are doing so while ensuring that the same high regulatory standards for quality, safety and<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/glossary/efficacy" style="color: purple; text-decoration: underline;" target="_blank" title="The measurement of a medicine's desired effect under ideal conditions, such as in a clinical trial."><span style="color: #004494;">efficacy</span></a><span class="Apple-converted-space"> </span>are being applied to COVID-19 vaccines.</span></span></p><p style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"><span style="font-family: arial;"><span face="Verdana, sans-serif" lang="EN" style="font-size: small;">The public meeting will inform citizens about EMA’s role in the pandemic and of EU regulatory procedures. It will also give the opportunity to the public and stakeholder groups to speak and share their needs, expectations and any concerns, that will be considered by EMA and the European medicines regulatory network in the decision-making process.</span></span></p><p style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"><span style="font-family: arial;"><span face="Verdana, sans-serif" lang="EN" style="font-size: small;">The EMA will publish the list of speakers who will make an intervention in advance of the event.</span></span></p><p style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"><span style="font-family: arial;"><span style="font-size: small;"><b><span face="Verdana, sans-serif" lang="EN">The public meeting will be broadcast live and will be open to all citizens</span></b><span face="Verdana, sans-serif" lang="EN">. In addition to the selected list of speakers, during the meeting there will be a mailbox open via EMA’s website for the public to make comments.</span></span></span></p><p style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"><span style="font-family: arial;"><span face="Verdana, sans-serif" lang="EN" style="font-size: small;">The agenda and all information related to the event are available on the EMA website<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/events/public-stakeholder-meeting-development-authorisation-safe-effective-covid-19-vaccines-eu" style="color: purple; text-decoration: underline;">event page</a>.</span></span></p><p class="MsoNormal" style="-webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin: 0cm 0cm 6pt; orphans: auto; text-align: start; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;"><span style="font-family: arial;"><span face="Verdana, sans-serif" style="font-size: small;">Please check EMA’s dedicated webpage on<span class="Apple-converted-space"> </span></span><span style="font-size: small;"><a href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19#what's-new-section" style="color: purple; text-decoration: underline;"><span face="Verdana, sans-serif">COVID-19</span></a><span face="Verdana, sans-serif"><span class="Apple-converted-space"> </span>for the latest updates.</span></span></span></p>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-62186679011485791212020-03-27T14:00:00.003-07:002020-03-27T14:00:48.876-07:00Updates from the European Medicines Agency re Covid-19: advice to continue use of ACE inhibitors and ARBs<div dir="ltr" style="text-align: left;" trbidi="on">
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">27.3.20: Briefing from the <a href="https://www.ema.europa.eu/en" target="_blank">European Medicines Agency</a></span></span></span></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">EMA reports that it is aware of recent <a href="https://www.thelancet.com/pdfs/journals/lanres/PIIS2213-2600(20)30116-8.pdf" style="color: purple; text-decoration: underline;" target="_blank"><span style="color: windowtext; text-decoration: none;">media reports and publications</span></a> which
question whether some medicines, for instance angiotensin converting
enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs, or
sartan medicines), could worsen<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19" style="color: purple; text-decoration: underline;" target="_self"><span style="color: windowtext; text-decoration: none;">coronavirus disease (COVID-19)</span></a>.
ACE inhibitors and ARBs are most commonly used for treating patients
with high blood pressure, heart failure or kidney disease. </span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">The EMA has providing the following </span></span><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;"><span style="color: black; display: inline; float: none; font-family: "verdana" , sans-serif; font-style: normal; font-weight: normal; letter-spacing: normal; text-decoration: none; text-indent: -2.2px; text-transform: none; white-space: normal; word-spacing: 0px;">advice from its Public and Stakeholders Engagement Department.</span></span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">"It
is important that patients do not interrupt their treatment with ACE
inhibitors or ARBs and there is no need to switch to other medicines.
There is currently no evidence from clinical or epidemiological studies
that establishes a link between ACE inhibitors or ARBs and the worsening
of COVID-19. Experts in the treatment of heart and blood pressure
disorders, including the European Society of Cardiology, have already
issued statements along those lines. To gather more evidence, EMA is
proactively reaching out to researchers working to generate further
evidence in epidemiological studies.</span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">As
the public health crisis rapidly extends across the globe, scientific
research is ongoing to understand how the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) reproduces in the body, interacts
with the immune system and causes disease, and whether ongoing treatment
with medicines such as ACE-inhibitors and ARBs could impact the
prognosis of COVID-19.</span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">The
speculation that ACE-inhibitors or ARBs treatment can make infections
worse in the context of COVID-19 is not supported by clinical evidence.
These medicines work by affecting the renin-angiotensin-aldosterone
system (RAAS). Because the virus uses a target called angiotensin
converting enzyme 2 (ACE2), which is part of this system, to enter human
cells, and the medicines can increase ACE2, one of the suggestions
among others is that they could also increase virus activity. However,
the interactions of the virus with the RAAS in the body are complex and
not completely understood.</span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">EMA
is monitoring the situation closely and is collaborating with
stakeholders to coordinate epidemiological studies on the effects of ACE
inhibitors and ARBs in people with COVID-19.</span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">EMA
is helping to coordinate urgent ongoing research and is fully committed
to keep the public up to date with any development in this field. EMA
is also aware of reports questioning whether other medicines such as
corticosteroids and non-steroidal anti-inflammatories (<a href="https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19" style="color: purple; text-decoration: underline;">NSAIDs</a>) could worsen COVID-19, and has recently issued a communication on<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19" style="color: purple; text-decoration: underline;"><span style="color: windowtext; text-decoration: none;">NSAIDs</span></a><span class="Apple-converted-space"> </span>medicines.
It is important that patients who have any questions or are uncertain
about their medicines speak to their doctor or pharmacist and do not
stop their regular treatment without speaking to their healthcare
professional first.</span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">Medicines
should be prescribed and used in line with clinical judgement, taking
due note of any warnings and other information provided in the<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/glossary/summary-product-characteristics" style="color: purple; text-decoration: underline;" target="_blank" title="A document describing the properties and the officially approved conditions of use of a medicine. Summaries of product characteristics form the basis of information for healthcare professionals on how to use the medicine safely and effectively. Abbreviate"><span style="color: windowtext; text-decoration: none;">summary of product characteristics</span></a><span class="Apple-converted-space"> </span>(SmPC) and the<a href="https://www.ema.europa.eu/en/glossary/package-leaflet" style="color: purple; text-decoration: underline;" target="_blank" title="The leaflet in every pack of medicine that contains information on the medicine for end-users, such as patients and animal owners."><span style="color: windowtext; text-decoration: none;">package leaflet</span></a>, as well as guidance issued by the WHO and relevant national and international bodies.</span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">Within
the EU medicines regulatory network, evidence on the safe use of
medicines is reviewed as it emerges. Any new advice that arises is
disseminated appropriately through<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19" style="color: purple; text-decoration: underline;"><span style="color: windowtext; text-decoration: none;">EMA</span></a><span class="Apple-converted-space"> </span>and<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/partners-networks/eu-partners/eu-member-states/national-competent-authorities-human" style="color: purple; text-decoration: underline;"><span style="color: windowtext; text-decoration: none;">national competent authorities</span></a>.</span></span></span></div>
<div style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin-bottom: 6pt; margin-left: 0cm; margin-right: 0cm; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;"><span style="border: 1pt none windowtext; padding: 0cm;">EMA will provide further information as appropriate.</span></span></span></div>
<div class="MsoNormal" style="-moz-text-size-adjust: auto; -webkit-text-stroke-width: 0px; caret-color: rgb(0, 0, 0); color: black; font-style: normal; font-variant-caps: normal; font-weight: normal; letter-spacing: normal; line-height: 14pt; margin: 0cm 0cm 6pt; text-align: left; text-decoration: none; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px;">
<span style="font-size: small;"><span style="font-family: "verdana" , sans-serif;">This information and related content are published<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic" style="color: purple; text-decoration: underline;">here</a>. Please check EMA’s dedicated webpage on<span class="Apple-converted-space"> </span><a href="https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19#what's-new-section" style="color: purple; text-decoration: underline;">COVID-19</a><span class="Apple-converted-space"> </span>for the latest updates."</span></span></div>
</div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-2223506196061095982019-09-25T06:03:00.000-07:002019-09-25T06:09:51.799-07:00Updates from the European Medicines Agency: from vaccines to repurposing medicines and pharmacovigilance <span style="font-size: small;"><br /></span>
<br />
<div class="separator" style="clear: both; text-align: center;">
<span style="font-size: small;"><a href="https://1.bp.blogspot.com/-cl0gyJ9Xq2M/XYtk-niUOeI/AAAAAAAACoY/YY5BR77dQr0BmX1fQqYQlDRvKlYBiFNUgCLcBGAsYHQ/s1600/IMG_1703.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="406" data-original-width="739" height="175" src="https://1.bp.blogspot.com/-cl0gyJ9Xq2M/XYtk-niUOeI/AAAAAAAACoY/YY5BR77dQr0BmX1fQqYQlDRvKlYBiFNUgCLcBGAsYHQ/s320/IMG_1703.jpg" width="320" /></a></span></div>
<div class="MsoNormal">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><b>24th-25th September</b><br />The European
Medicines Agency has hosted its first meetings in Amsterdam for its Healthcare Professional Working Party and Patient and
Consumers Working Party since the move of the Agency from its former Canary Wharf headquarters in London. The sessions coincided with the launch of a further three year work
programme agreed between the EMA and its working parties. </span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><br />
<div class="MsoNormal">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><a href="https://www.ema.europa.eu/en/events/european-medicines-agency-ema-joint-patients-consumers-pcwp-healthcare-professionals-hcpwp-meeting">Papers
from the meetings will be available on the EMA website.</a> </span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Key themes in the
new work programme will include secure supply of medicines,
digital media for health, public health strategy on antibiotic resistance,
addressing vaccine hesitancy, early access to medicines, pharmacovigilance, and
encouraging patient engagement. </span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><span style="font-size: small;"><a href="https://1.bp.blogspot.com/-W-JtmYruPdI/XYtk-jafMpI/AAAAAAAACoU/236hGmoO46UE5NCZL9xriPM9TITDTkrCgCEwYBhgL/s1600/IMG_1637.JPG" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="1200" data-original-width="1600" height="240" src="https://1.bp.blogspot.com/-W-JtmYruPdI/XYtk-jafMpI/AAAAAAAACoU/236hGmoO46UE5NCZL9xriPM9TITDTkrCgCEwYBhgL/s320/IMG_1637.JPG" width="320" /></a></span></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-size: small;"><b><span style="font-family: "arial" , "helvetica" , sans-serif;">Central Amsterdam</span></b></span></td></tr>
</tbody></table>
<div class="MsoNormal">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Major topics discussed during the current Amsterdam
meetings included initiatives to address vaccine hesitancy, updates on
pharmacovigilance and initiatives on repurposing of medicines. In addition, the
EMA provided updates from its <a href="https://www.ema.europa.eu/en/committees/committee-herbal-medicinal-products-hmpc">major
standing committees</a>, including the <span lang="EN-US">Committee
for Orphan Medicinal Products (COMP)</span>, <span lang="EN-US">Pharmacovigilance Risk Assessment
Committee (PRAC)</span>, <span lang="EN-US">Committee for Advanced Therapies (CAT)</span>, <span lang="EN-US">Committee
for Medicinal Products for Human Use (CHMP)</span>, <span lang="EN-US">Paediatric Committee
(PDCO) </span>and <span lang="EN-US">Committee on Herbal Medicinal Products (HMPC)</span>.<br /><br />Isabel de la
Mata, Principal Advisor on Public Health and Crisis Management at the European
Commission discussed current initiatives to address vaccine hesitancy, an early
priority of EU President-elect Ursula van der Leyer.<br /><br />De la Mata noted
that vaccine coverage is below 95% in many EU member states. A 2019
Eurobarometer on vaccine confidence had highlighted several key points of misinformation,
for example with 48% of respondents thinking that vaccines often produce
serious side effects, 38% that vaccines can cause the disease they prevent and
55% considering that vaccines overload and weaken the immune system. <br /><br />A Global
Vaccination Summit had been held on 12<sup>th</sup> September with around 400
delegates political, technical, patients and other - and with WHO collaboration.
This led to a 10 point document including new focus on reliable access to
vaccines, safety and transparent, clear, independent information. <br /><br />Actions by member
states are to include developing national and regional plans, better access to
vaccines, increased public health communications, more training of health
professionals, accurate digital information on vaccination status and increased
support for vaccine research and innovation.<br /><br />European level
actions are to include a new European Vaccination portal coordinated by ECDC (European
Centre for Disease Control) with support from the EMA (EVIS - European Vaccine
Information Sharing). Other work will consider dissemination of vaccine
schedules, focus on the supply chain, including mitigating shortages and
identifying and overcoming barriers to access.<br /><br />A new coalition
of healthcare workers for vaccination, launched on 5<sup>th</sup> March in Brussels,
aims to address and reverse reasons for outbreaks of measles and other
vaccine-preventable infections in health workers as recently as 2017 and 2018,
with transmission in the healthcare setting even in countries with high
vaccination coverage.<br /><br />John Kinsman,
Expert in Social and Behavioural Change Communication at the ECDC, outlined
Development of the European Vaccination information Portal. This is due to be
piloted in December 2019 and launched in April 2020 during European
Immunisation week.</span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><br />
<div class="MsoNormal">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">The portal has a
legal basis, arising from a 2016 European Commission call for the ECDC to work
with EMA to develop the portal. Issues
include the reality that the majority of the public do not have a scientific
background and making sure through content, language and accessibility that the
portal is as widely available as possible.<br /><br />The EMA is seeing
an exponential increase in reporting by patients of suspected adverse drug
reactions. A pressing aim of the EMA is
how best to learn from patient reporting of possible ADR. This will benefit
from previous experience of patient reporting to national competent
authorities (e.g. US FDA and UK MHRA
[patient reporting since September 2005]) and international agencies (e.g. the
WHO Uppsala Monitoring Centre).<br /><br />Plans for future
meetings include proposals for further discussion of initiatives on vaccine
uptake.</span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><style><font size="3"><span style="font-family: Arial, Helvetica, sans-serif;">
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
mso-themecolor:hyperlink;
text-decoration:underline;
text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-noshow:yes;
mso-style-priority:99;
color:purple;
mso-themecolor:followedhyperlink;
text-decoration:underline;
text-underline:single;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</span></font></style>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-19801991414932968812019-07-08T10:26:00.002-07:002019-07-08T16:26:12.142-07:00Hear from Prof Harry Sokol why gut microbiota are so important for human diseases and their treatments<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">The <a href="http://eacpt.eu/">14th EACPT Congress</a> was held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics.</span></span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">The term <a href="https://gut.bmj.com/content/65/2/330.full">gut microbiota</a> describes </span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span class="ILfuVd"><span class="e24Kjd">the population of microbes living in our intestines. Gut microbiota are being increasingly recognised as important contributors to a wide range of human diseases, from disorders of the gut to cancers and neurological disease.</span></span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span class="ILfuVd"><span class="e24Kjd"><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span class="ILfuVd"><span class="e24Kjd">Gut microbiota also contribute</span></span></span></span> to drug response and to risk of adverse drug effects. Gut microbiota also provide a source of potential treatments.</span></span></span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">In this
short video you can hear keynote EACPT Congress speaker </span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><a href="https://www.micalis.fr/micalis_eng/Poles-and-teams/Pole-Food-and-Digestive-Ecosystems/Interactions-of-Commensal-and-Probiotic-Bacteria-with-the-Host-Phillipe-Langella/P.-Langella-and-4-Groups/Harry-Sokol">Professor Harry Sokol </a>from Paris</span></span></span> discuss the importance for clinical pharmacologists, other health professionals and patients of understanding emerging key roles for gut microbiota in serious diseases and their treatments.</span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><br /></span></span>
<br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/ok5DDzWkK9M/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/ok5DDzWkK9M?feature=player_embedded" width="320"></iframe></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><br /></span></span>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><b><span lang="EN-US">Discussants</span></b></span></span>
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><a href="https://www.micalis.fr/micalis_eng/Poles-and-teams/Pole-Food-and-Digestive-Ecosystems/Interactions-of-Commensal-and-Probiotic-Bacteria-with-the-Host-Phillipe-Langella/P.-Langella-and-4-Groups/Harry-Sokol"><span style="color: black;"><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"></span></span></span>Professor Harry </span><span style="color: black;">Sokol</span></a></span><span style="font-size: small;"><span style="color: black;">, Hôpital</span><span style="color: black;"> </span><span style="color: black;">Saint-</span><span style="color: black;">Antoine and Sorbonne University, Paris, France</span></span><span style="font-size: small;"><span style="color: black;"><br />in discussion with<br /><a href="https://www.eacpt.eu/eacpt-committees/tabassome-simon/">Professor </a></span><span style="color: black;"><a href="https://www.eacpt.eu/eacpt-committees/tabassome-simon/">Tabassome</a></span><span style="color: black;"><a href="https://www.eacpt.eu/eacpt-committees/tabassome-simon/"> Simon</a>, EACPT Past-President </span></span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><b><br />The next EACPT Congress</b><br />The next EACPT biennial congress will be
held in Athens in June 2019. The programme will provide
an international scientific and educational forum for discussion of clinical
pharmacology and therapeutics, including personalised pharmacotherapy. <a href="http://eacpt.eu/">See more on our website</a>.<br /><br /><b>Joining the EACPT</b><br />Anyone from anywhere in the world with a
professional interest in clinical pharmacology and therapeutics can now <a href="https://www.eacpt.eu/register/">join the EACPT as an Individual Associate member.</a><br /><br />Membership benefits include: </span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
<span lang="EN-US">* Discounted registration fees for EACPT
meetings</span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">* Online subscription to the EACPT Official journal: t<a href="https://link.springer.com/journal/228">he European Journal of Clinical Pharmacology </a><br />* Access to the EACPT’s worldwide
network of Individual Associate Members<br />* Active involvement in EACPT <b><br /><br />25th Anniversary</b><br />The EACPT was founded 25 years ago and
now includes as members all major national organisations for clinical pharmacology in
Europe, as well as organisations from further afield internationally. The EACPT
aims to provide educational and scientific support for the more than 4000
individual professionals interested in clinical pharmacology and therapeutics
throughout the European region, with its congresses attended by a global
audience. The EACPT also advises policy makers on how the specialty can
contribute to human health and wealth. <a href="https://link.springer.com/article/10.1007/s00228-019-02690-5">Find out more about the EACPT ...</a></span><b><span lang="EN-US"><br /><br />Future EACPT Congresses</span></b></span></span><br />
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2021 Athens</span></span></span></div>
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2023 Rotterdam</span></span></span></div>
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2025 Helsinki </span></span></span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-38120696770734677092019-07-03T13:49:00.000-07:002019-07-08T02:27:57.117-07:00Meeting global health challenges: Karolinska President discusses how Clinical Pharmacologists can help<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span lang="EN-US">The <a href="http://eacpt.eu/">14th EACPT Congress</a> was held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics.</span></span></span><br />
<div class="MsoPlainText">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><br /><span lang="EN-US"></span></span></span></div>
<div class="MsoPlainText">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Keynote opening speaker at the EACPT Congress </span></span><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><a href="https://ki.se/en/about/president-ole-petter-ottersen"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="color: black;">Professor Ole</span><span style="color: black;"> </span><span style="color: black;">Petter</span><span style="color: black;"> </span><span style="color: black;">Ottersen</span></span></span></a> discusses how Clinical Pharmacologists in Europe and beyond can help to meet current global health challenges. In particular he notes that 14 of the 17 current WHO strategic development goals are relevant to safe, effective and equitable use of medicines. He also stresses the need to be aware of and address 'sticky institutions', whether governmental, NGO or commercial as barriers to improving global health policy and its implementation.</span></span></div>
<div class="MsoPlainText">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Professor Ottersen chaired the international Lancet Commission that studied the political determinants of
global health inequalities (<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62407-1/fulltext">The Lancet-University of Oslo Commission on Global Governance for Health</a>).</span></span><br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/O52Ph78UN9U/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/O52Ph78UN9U?feature=player_embedded" width="320"></iframe></div>
</div>
<div class="MsoPlainText">
</div>
<div class="MsoPlainText">
</div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">
<b><span lang="EN-US">Discussants</span></b>
<span lang="EN-US"> </span></span></span><a href="https://ki.se/en/about/president-ole-petter-ottersen"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="color: black;"><br />Professor Ole</span><span style="color: black;"> </span><span style="color: black;">Petter</span><span style="color: black;"> </span><span style="color: black;">Ottersen</span></span></span></a><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="color: black;">, President, </span><span style="color: black;">Karolinska</span><span style="color: black;"> Institute</span></span></span>
<br />
<div class="MsoPlainText">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"></span></span><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span lang="EN-US"> Professor Donald Singer: co-opted member of the
Executive Committee of the EACPT.</span></span></span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"></span><br />
<div style="direction: ltr; margin-bottom: 0pt; margin-left: 0in; margin-top: 10.56pt; mso-line-break-override: none; punctuation-wrap: hanging; text-align: center; text-indent: 0in; unicode-bidi: embed; word-break: normal;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"></span></span></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span lang="EN-US"></span></span></span><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span lang="EN-US"><b>The next EACPT Congress</b><br />The next EACPT biennial congress will be
held in Athens. The programme will provide
an international scientific and educational forum for discussion of clinical
pharmacology and therapeutics, including personalised pharmacotherapy. <a href="http://eacpt.eu/">See more on our website</a>.<br /><br /><b>Joining the EACPT</b><br />Anyone from anywhere in the world with a
professional interest in clinical pharmacology and therapeutics can now <a href="https://www.eacpt.eu/register/">join the EACPT as an Individual Associate member.</a><br /><br />Membership benefits include: </span></span></span></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">
<span lang="EN-US">* Discounted registration fees for EACPT
meetings</span><br />
<span lang="EN-US">* Online subscription to the EACPT Official journal: t<a href="https://link.springer.com/journal/228">he European Journal of Clinical Pharmacology </a><br />* Access to the EACPT’s worldwide
network of Individual Associate Members<br />* Active involvement in EACPT <b><br /><br />25th Anniversary</b><br />The EACPT was founded 25 years ago and
now includes as members all major national organisations for clinical pharmacology in
Europe, as well as organisations from further afield internationally. The EACPT
aims to provide educational and scientific support for the more than 4000
individual professionals interested in clinical pharmacology and therapeutics
throughout the European region, with its congresses attended by a global
audience. The EACPT also advises policy makers on how the specialty can
contribute to human health and wealth. <a href="https://link.springer.com/article/10.1007/s00228-019-02690-5">Find out more about the EACPT ...</a></span><b><span lang="EN-US"><br /><br />Future EACPT Congresses</span></b><br />
</span></span><br />
<div class="MsoPlainText">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span lang="EN-US">2021 Athens</span></span></span></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">
</span></span>
<br />
<div class="MsoPlainText">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span lang="EN-US">2023 Rotterdam</span></span></span></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">
</span></span>
<br />
<div class="MsoPlainText">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span lang="EN-US">2025 Helsinki </span></span></span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-28492193379239719062019-07-03T13:37:00.001-07:002019-07-08T02:27:24.666-07:00Ubiquitous Pharmacogenomcs - adopting testing for genetic variability in drug response in clinical practice<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">The <a href="http://eacpt.eu/">14th EACPT Congress</a> was held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics.</span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><br />Understanding how genetic variability influences both the desired response to medicines and risk of adverse drug reactions has the potential improve the benefits and reduce the risks of treatment with medicines. In this
short video you can hear keynote EACPT Congress speaker </span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">Professor Henk-Jan Guchelaar</span></span></span> discuss how clinical pharmacologists can implement these pharmacogenetic tests into clinical practice..</span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">Professor Guchelaar coordinates a European Horizon 2020 project - U-PGx: <a href="http://upgx.eu/">Ubiquitous Pharmacogenomics</a> - about
implementation of pharmacogenetics in routine health care. </span></span></span></span></span><br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/sSFjIWieTcg/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/sSFjIWieTcg?feature=player_embedded" width="320"></iframe></div>
</div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><b><span lang="EN-US">Discussants</span></b></span></span>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"> </span></span></span><br />
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><a href="https://www.universiteitleiden.nl/en/staffmembers/henk-jan-guchelaar#tab-1">Professor Henk-Jan Guchelaar</a>, </span></span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">Head of the Department of Clinical Pharmacy & Toxicology </span></span></span>Leiden
University Medical Centre.</span><span lang="EN-US"><br />Professor Donald Singer: co-opted member of the
Executive Committee of the EACPT.</span><br /><span lang="EN-US"> </span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><b>The next EACPT Congress</b><br />The next EACPT biennial congress will be
held in Athens. The programme will provide
an international scientific and educational forum for discussion of clinical
pharmacology and therapeutics, including personalised pharmacotherapy. <a href="http://eacpt.eu/">See more on our website</a>.<br /><br /><b>Joining the EACPT</b><br />Anyone from anywhere in the world with a
professional interest in clinical pharmacology and therapeutics can now <a href="https://www.eacpt.eu/register/">join the EACPT as an Individual Associate member.</a><br /><br />Membership benefits include: </span></span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
<span lang="EN-US">* Discounted registration fees for EACPT
meetings</span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">* Online subscription to the EACPT Official journal: t<a href="https://link.springer.com/journal/228">he European Journal of Clinical Pharmacology </a><br />* Access to the EACPT’s worldwide
network of Individual Associate Members<br />* Active involvement in EACPT <b><br /><br />25th Anniversary</b><br />The EACPT was founded 25 years ago and
now includes as members all major national organisations for clinical pharmacology in
Europe, as well as organisations from further afield internationally. The EACPT
aims to provide educational and scientific support for the more than 4000
individual professionals interested in clinical pharmacology and therapeutics
throughout the European region, with its congresses attended by a global
audience. The EACPT also advises policy makers on how the specialty can
contribute to human health and wealth. <a href="https://link.springer.com/article/10.1007/s00228-019-02690-5">Find out more about the EACPT ...</a></span><b><span lang="EN-US"><br /><br />Future EACPT Congresses</span></b></span></span><br />
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2021 Athens</span></span></span></div>
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2023 Rotterdam</span></span></span></div>
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2025 Helsinki </span></span></span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-78077177137232561092019-07-01T23:35:00.005-07:002019-07-03T13:17:55.808-07:00Markus Zeitlinger in Stockholm at EACPT Congress discussing better use of antibiotics<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">The <a href="http://eacpt.eu/">14th EACPT Congress</a> is being held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics.</span></span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><br /><br />Failure to respond to antibiotics is a major international concern. In this short video you can hear keynote EACPT Congress speaker Professor Markus Zeitlinger discuss how clinical pharmacologists can help to improve the effects of antibiotics by careful monitoring of drug levels and the patient's response to these powerful medicines.</span></span></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen="" class="YOUTUBE-iframe-video" data-thumbnail-src="https://i.ytimg.com/vi/lttUb43ZSlM/0.jpg" frameborder="0" height="266" src="https://www.youtube.com/embed/lttUb43ZSlM?feature=player_embedded" width="320"></iframe></div>
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><b><span lang="EN-US">Discussants</span></b></span></span>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"> </span></span></span><br />
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">Professor <a href="https://klpharm.meduniwien.ac.at/organization/section-of-clinical-pharmacokinetics-pharmacogenetics-and-imaging/team/markus-zeitlinger/">Markus Zeitlinger</a>, </span><span lang="EN-US">Head of the Department of Clinical Pharmacology, Medical University of Vienna<br />Professor Donald Singer: co-opted member of the
Executive Committee of the EACPT.</span><span lang="EN-US"></span><br /><span lang="EN-US"> </span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><b>The next EACPT Congress</b><br />The next EACPT biennial congress will be
held in Athens. The programme will provide
an international scientific and educational forum for discussion of clinical
pharmacology and therapeutics, including personalised pharmacotherapy. <a href="http://eacpt.eu/">See more on our website</a>.<br /><br /><b>Joining the EACPT</b><br />Anyone from anywhere in the world with a
professional interest in clinical pharmacology and therapeutics can now <a href="https://www.eacpt.eu/register/">join the EACPT as an Individual Associate member.</a><br /><br />Membership benefits include: </span></span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
<span lang="EN-US">* Discounted registration fees for EACPT
meetings</span></span></span><br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">* Online subscription to the EACPT Official journal: t<a href="https://link.springer.com/journal/228">he European Journal of Clinical Pharmacology </a><br />* Access to the EACPT’s worldwide
network of Individual Associate Members<br />* Active involvement in EACPT <b><br /><br />25th Anniversary</b><br />The EACPT was founded 25 years ago and
now includes as members all major national organisations for clinical pharmacology in
Europe, as well as organisations from further afield internationally. The EACPT
aims to provide educational and scientific support for the more than 4000
individual professionals interested in clinical pharmacology and therapeutics
throughout the European region, with its congresses attended by a global
audience. The EACPT also advises policy makers on how the specialty can
contribute to human health and wealth. <a href="https://link.springer.com/article/10.1007/s00228-019-02690-5">Find out more about the EACPT ...</a></span><b><span lang="EN-US"><br /><br />Future EACPT Congresses</span></b></span></span><br />
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2021 Athens</span></span></span></div>
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2023 Rotterdam</span></span></span></div>
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">2025 Helsinki </span></span></span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-76754979453716617952019-07-01T07:53:00.002-07:002019-07-01T07:53:52.131-07:00Delegates at 14th EACPT Congress in early morning Stockholm run<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">The <a href="http://eacpt.eu/">14th EACPT Congress</a> is being held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics. </span></span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Beating the summer heat by a 7am start, delegates from a wide range of countries took part in a run along the quiet streets of the Swedish capital city. </span></span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">You can see below some of the delegates who took part, in photos provided by runner Professor Gerard Rongen, lead organiser of the 6th EACPT Congress, to be held in 2023 in Rotterdam.</span></span><br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-jc-xn0dhie8/XRoeCO6EhxI/AAAAAAAACl8/2lWo3yibY-sfiXQ_KYRAI76IqZmP-sJ_wCLcBGAs/s1600/IMG_7086.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1080" data-original-width="1440" height="240" src="https://1.bp.blogspot.com/-jc-xn0dhie8/XRoeCO6EhxI/AAAAAAAACl8/2lWo3yibY-sfiXQ_KYRAI76IqZmP-sJ_wCLcBGAs/s320/IMG_7086.JPG" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-VLq1-YHSPmc/XRoeB1IeI_I/AAAAAAAACl4/gwiibe0RtUg76xlYlPe7QDgqI45xIeFOQCLcBGAs/s1600/IMG_7088.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="817" data-original-width="1019" height="256" src="https://1.bp.blogspot.com/-VLq1-YHSPmc/XRoeB1IeI_I/AAAAAAAACl4/gwiibe0RtUg76xlYlPe7QDgqI45xIeFOQCLcBGAs/s320/IMG_7088.JPG" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-up_3apx9I00/XRoeCA48pwI/AAAAAAAACmA/lh4FArwdTMU5JbwD7JA9W5Y9evz3N-NhwCLcBGAs/s1600/IMG_7089.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1022" data-original-width="1075" height="304" src="https://1.bp.blogspot.com/-up_3apx9I00/XRoeCA48pwI/AAAAAAAACmA/lh4FArwdTMU5JbwD7JA9W5Y9evz3N-NhwCLcBGAs/s320/IMG_7089.JPG" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-2OfvbfPARXk/XRoeMReCPYI/AAAAAAAACmE/JBCxet1lEeQ0wifhnKVdRCuT8HNAJ96SACLcBGAs/s1600/IMG_7091.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="719" data-original-width="987" height="233" src="https://1.bp.blogspot.com/-2OfvbfPARXk/XRoeMReCPYI/AAAAAAAACmE/JBCxet1lEeQ0wifhnKVdRCuT8HNAJ96SACLcBGAs/s320/IMG_7091.JPG" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-VdY_6jdDUbM/XRoeMknHDHI/AAAAAAAACmM/wAGNm3TC5pwZX7iTeroW1jfZFkuyHnJ6QCLcBGAs/s1600/IMG_7093.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="958" data-original-width="1005" height="305" src="https://1.bp.blogspot.com/-VdY_6jdDUbM/XRoeMknHDHI/AAAAAAAACmM/wAGNm3TC5pwZX7iTeroW1jfZFkuyHnJ6QCLcBGAs/s320/IMG_7093.JPG" width="320" /></a></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-VSjh8-tx12M/XRoeMn657wI/AAAAAAAACmI/tz-_20GLaAYSRHlYgSEBevSGFMdr28zcwCLcBGAs/s1600/IMG_7095.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="736" data-original-width="934" height="252" src="https://1.bp.blogspot.com/-VSjh8-tx12M/XRoeMn657wI/AAAAAAAACmI/tz-_20GLaAYSRHlYgSEBevSGFMdr28zcwCLcBGAs/s320/IMG_7095.JPG" width="320" /></a></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"></span></span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">Opportunities for EACPT Individual Associate Members include</span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">* discounted registration fees for EACPT meetings<br />
* networking with colleagues worldwide through the global EACPT network of
Individual Associate Members <br />
* active involvement in EACPT Working Parties and other activities<span style="color: blue;"> </span></span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="color: blue;"> </span></span>
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><a href="https://www.eacpt.eu/register/">Find out how to become an
Associate Member of the EACPT</a> </span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">Future EACPT Congresses will be held in: <br />
- 2021 Athens<br />
- 2023 Rotterdam</span>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-75434657321677423922019-06-30T05:40:00.000-07:002019-06-30T05:42:13.652-07:002019 EACPT Scientific Award goes to David Brinkman for paper on CPT education<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-2BlNgzKLqRo/XRitU3J_SsI/AAAAAAAACls/aCUInojBOdUVyK07ICzU6aq-WJ-p-MQ6wCLcBGAs/s1600/Slide1.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="540" data-original-width="720" height="240" src="https://1.bp.blogspot.com/-2BlNgzKLqRo/XRitU3J_SsI/AAAAAAAACls/aCUInojBOdUVyK07ICzU6aq-WJ-p-MQ6wCLcBGAs/s320/Slide1.jpg" width="320" /></a></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;">Congratulations to David Brinkman from the
Department of Internal Medicine at the VU University Medical Centre in
Amsterdam who has won 2019 EACPT Scientific Award for the best scientific paper
on a clinical pharmacology or therapeutic theme in the previous 2 years.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">His winning paper on “<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099198/pdf/CPT-104-317.pdf">Key
Learning Outcomes for Clinical Pharmacology and Therapeutics Education in
Europe: A Modified Delphi Study” was published in Clinical Pharmacology and
Therapeutics</a> [2018;104:317-325]. Dr Brinkman will receive the EACPT
Scientific Award on Tuesday 2nd July during the 14th biennial EACPT Congress in
Stockholm.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">David Brinkman was the first author of the
report, which he co-authored with international colleagues from the Education
Working Group of the European Association for Clinical Pharmacology and
Therapeutics (EACPT) and its affiliated Network of Teachers in Pharmacotherapy.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">Recent studies had reported both that the
prescribing competencies of final-year medical students in Europe were poor,
which if happening in clinical practice could result in potentially harmful
prescribing errors; and that there is marked variation in CPT education within
and between European countries.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">In the paper, key learning outcomes were
identified for teaching and assessing CPT in undergraduate medical curricula in
Europe.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">A large European expert panel reached
consensus on 252 key learning outcomes that should be included in undergraduate
CPT curricula to ensure that European graduates are able to prescribe safely
and effectively. The panel also provided a blueprint of a European core
curriculum in CPT, including key learning outcomes and how they might be taught
and assessed during undergraduate medical training.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">The paper concluded that a European core
curriculum in CPT might help to harmonize CPT education and improve the
prescribing competencies of future European doctors and thereby patient safety.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">EACPT Congress will be held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics. </span> </span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">Opportunities for EACPT Associate Members include</span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">* discounted registration fees for EACPT meetings<br />
* networking with colleagues worldwide through the global EACPT network of
Associate Members <br />
* active involvement in EACPT Working Parties and other activities<span style="color: blue;"> </span></span>
<br />
<div class="MsoNormal" style="margin-bottom: 5.0pt;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><a href="https://www.eacpt.eu/register/">Find out how to become an
Associate Member of the EACPT</a> </span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">Future EACPT Congresses will be held in: <br />
- 2021 Athens<br />
- 2023 Rotterdam</span> <span style="font-family: "arial" , "helvetica" , sans-serif;"></span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><br />
The EACPT was founded in 1993 and now includes as members all national
organisations for clinical pharmacology in Europe, as well as organisations
from further afield internationally. The EACPT aims to provide educational and
scientific support for the more than 4000 individual professionals interested
in clinical pharmacology and therapeutics throughout the European region, with
its congresses attended by a global audience. The EACPT also advises policy
makers on how the specialty can contribute to human health and wealth.</span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-92134474924583283512019-04-06T02:38:00.000-07:002019-04-06T13:27:09.576-07:00Tomorrow's medicines: key programme talks announced for EACPT Stockholm Congess 29 June - 2 July 2019
<div class="separator" style="clear: both; text-align: center;">
<a href="https://2.bp.blogspot.com/-ub58ECXi3us/XGIHGmdixJI/AAAAAAAAChs/qQqaVlZXclcrubCO40pFxCtnJeS4fKwZACPcBGAYYCw/s1600/EACPT_banner_Kastellholmen_Photo_Jeppe-Wikstrom_21-1320x440.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="440" data-original-width="1320" height="106" src="https://2.bp.blogspot.com/-ub58ECXi3us/XGIHGmdixJI/AAAAAAAAChs/qQqaVlZXclcrubCO40pFxCtnJeS4fKwZACPcBGAYYCw/s320/EACPT_banner_Kastellholmen_Photo_Jeppe-Wikstrom_21-1320x440.jpg" width="320" /></a></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">The next <a href="http://www.eacpt2019.org/">EACPT Congress</a> will be held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics. </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<a href="http://www.eacpt2019.org/registration/"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Early bird registration deadline - 10th April 2019. Register online for the 2019 EACPT Congress in Stockholm</span></a></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">The Congress will address Tomorrow's Healthcare Challenges and will be
held at the City Conference Centre - 5 minutes from Stockholm Central Station.</span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">The Congress Reception on the evening of Saturday 29th June, will be
held at Stockholm City Hall, the venue of the Nobel Prize banquet.</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">The Keynote Opening Lecture will be given by the President at the
Karolinska Institute, Professor Ole Petter Ottersen, on global health and
clinical pharmacology.</span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Professor Urs Meyer from Switzerland will give the 2019 EACPT Lifetime
Achievement Award Lecture based on his work on individual variation in drug
response.</span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Further awards will be presented, including Scientific Awards, including
Young Investigator, and EACPT Education Awards. </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Around 60 invited speakers are expected from throughout Europe and
beyond. Congress keynote lectures will include:</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Plenary lectures</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Ylva Böttiger:<span style="mso-spacerun: yes;"> </span>Clinical
pharmacology reaching out - 25 years with EACPT </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Ole Petter Ottersen:<span style="mso-spacerun: yes;"> </span>Global
health research and education in Europe - how can clinical pharmacology
contribute? </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Harry Sokol:<span style="mso-spacerun: yes;"> </span>Gut microbiota - a
new actor in pharmacology? </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Urs Meyer:<span style="mso-spacerun: yes;"> </span>Therapeutic Lessons
from Human Individuality </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Rosa Giuliani:<span style="mso-spacerun: yes;"> </span>Update on treating
breast cancer </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Jenny Kindblom:<span style="mso-spacerun: yes;"> </span>Pediatric
clinical trials and their pitfalls </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Tim Nicholson:<span style="mso-spacerun: yes;"> </span>New targets in
psychopharmacology </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Sylvie Laporte:<span style="mso-spacerun: yes;">
</span>Meta-epidemiological studies to detect, quantify and adjust for bias in
open-label trials </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Stefan James:<span style="mso-spacerun: yes;"> </span>Innovative ways of performing
clinical trials </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Björn Wettermark:<span style="mso-spacerun: yes;"> </span>How to measure
drug utilisation </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Cardiovascular prevention</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Stephane Laurent:<span style="mso-spacerun: yes;"> </span>Update on
treating hypertension </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Gerard Rongen:<span style="mso-spacerun: yes;"> </span>PCSK9 inhibitors -
going lower but for whom and at what price? Paul Hjemdahl:<span style="mso-spacerun: yes;"> </span>Dual or triple antithrombotic therapy - is
two company and three a crowd? </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">An ageing population</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Denis O'Mahoney:<span style="mso-spacerun: yes;"> </span>STOPP/START
decision support for elderly prescribing </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Anne Spinewine:<span style="mso-spacerun: yes;"> </span>Prescribing in
the frail elderly </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;"><span style="mso-spacerun: yes;"> </span></span></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Workshops</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Martin Henriksson:<span style="mso-spacerun: yes;"> </span>How to perform
a health economic study </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Olof Beck and Markus Meyer: How to measure drug exposure </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Jan Marcusson:<span style="mso-spacerun: yes;"> </span>How to make on
oral presentation and feel good about it </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Closing the money gap</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Gerd Lärfars:<span style="mso-spacerun: yes;"> </span>Horizon scanning
frontiers </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Andras Inotai:<span style="mso-spacerun: yes;"> </span>How to solve money
gap to ensure patient access to pharmaceuticals in EU counties </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">David Webb:<span style="mso-spacerun: yes;"> </span>Health economics: big
ideas from a small country </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Personalized medicine : joint
EACPT-EPHAR session</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Henk Jan Guchelaar:<span style="mso-spacerun: yes;"> </span>Clinical
implementation of pharmacogenetics </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Viktor Hlavac:<span style="mso-spacerun: yes;"> </span>Pharmacogenetics
of cancer chemoresistance </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Seppo Ylä-Herttuala:<span style="mso-spacerun: yes;">
</span>Cardiovascular gene therapy </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Martina Schusler-Lenz:<span style="mso-spacerun: yes;"> </span>Advanced
therapy regulation in the EU </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Interprofessional working</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Ann Lykkegaard Sørensen:<span style="mso-spacerun: yes;">
</span>Interprofessional approach for safer medication in psychiatry </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Hanna Seidling:<span style="mso-spacerun: yes;"> </span>Benchmarks for
successful interdisciplinary collaboration </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Debate: Deprescribing is Dangerous </span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Jamie Coleman: For; Wade Thompson : Against </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Targeting small populations</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Caridad Pontes: barriers to market access,<span style="mso-spacerun: yes;"> </span></span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Violeta Stoyanova: drug designation and other regulatory
challenges </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Critically ill patients</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Dario Cattaneo:<span style="mso-spacerun: yes;"> </span>Anti-infectives
in intensive care </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Philippe Vignon:<span style="mso-spacerun: yes;"> </span>New sepsis drugs
in the pipeline: any reason for hope?</span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Christoph Stein:<span style="mso-spacerun: yes;"> </span>New concepts in
opioid analgesia </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Antibiotic drug resistance</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Johan Mouton:<span style="mso-spacerun: yes;"> </span>Antimicrobial
resistance. Could PK/PD be the answer? </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Alexandra Aubry:<span style="mso-spacerun: yes;"> </span>New treatment
options for resistent tuberculosis </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Polypharmacy: joint session with the
Korean Society</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Howard Lee:<span style="mso-spacerun: yes;"> </span>Polypharmacy in Korea
</span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Ho Sook Kim:<span style="mso-spacerun: yes;"> </span>The clinical
pharmacology perspectives for the optimal polypharmacy in Korea </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Kees Kramers:<span style="mso-spacerun: yes;"> </span>Polypharmacy:
Acting on the cutting edge of safety, efficacy and compliance </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Patient empowerment</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Bettina Ryll:<span style="mso-spacerun: yes;"> </span>Patient empowerment:
Issues with introduction of a new class of drugs </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Ann Langius Eklöf:<span style="mso-spacerun: yes;"> </span>Smart phones
provide smart patients </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">2020 drug strategy</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Jordi Llinares: achievements and future initiatives; Drug
regulation in the 2020s:<span style="mso-spacerun: yes;"> </span>Gonzalo Calvo:
an academic perspective; Graziella Collu: a pharmaceutical industry perspective
</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Decision support</span></b></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Matthew Doogue:<span style="mso-spacerun: yes;"> </span>Alert, clinical
decision support helping patients and hindering work flow </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: Arial; font-size: 12.0pt;">Lars L Gustafsson:<span style="mso-spacerun: yes;"> </span>Clinical
pharmacologists with computers - the way forward </span></div>
<div class="MsoPlainText">
<br /></div>
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
{mso-style-priority:99;
mso-style-link:"Plain Text Char";
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.5pt;
font-family:Courier;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
span.PlainTextChar
{mso-style-name:"Plain Text Char";
mso-style-priority:99;
mso-style-unhide:no;
mso-style-locked:yes;
mso-style-link:"Plain Text";
mso-ansi-font-size:10.5pt;
mso-bidi-font-size:10.5pt;
font-family:Courier;
mso-ascii-font-family:Courier;
mso-hansi-font-family:Courier;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 45.45pt 72.0pt 45.45pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-55755424018504186722019-04-05T02:36:00.000-07:002019-04-05T07:34:15.010-07:00Updates on the EACPT from Athens<br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://2.bp.blogspot.com/-BzxuTHG5yOY/XKchMgS5FgI/AAAAAAAACjE/9PkQYDLLr5gJnRZR6kdSl_lAdG3AzQkngCLcBGAs/s1600/r%2BParthenon.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="298" data-original-width="413" height="230" src="https://2.bp.blogspot.com/-BzxuTHG5yOY/XKchMgS5FgI/AAAAAAAACjE/9PkQYDLLr5gJnRZR6kdSl_lAdG3AzQkngCLcBGAs/s320/r%2BParthenon.jpg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Parthenon, Athens</span></td></tr>
</tbody></table>
<div class="MsoNormal" style="margin-bottom: 12.0pt;">
<span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">The EACPT
Executive Committee is meeting in Athens from 5<sup>th</sup> – 6<sup>th</sup>
April 2019 to plan for future activities of the EACPT.</span><br />
<span class="MsoPageNumber"><span lang="EN-US" style="font-family: "arial";"><span style="mso-bidi-font-weight: bold;"></span></span></span>
<br />
<span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">Main topics
for discussion include </span></div>
<div class="MsoListParagraphCxSpFirst" style="margin-bottom: 12.0pt; mso-add-space: auto; mso-list: l0 level1 lfo2; text-indent: -18.0pt;">
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: Arial; mso-fareast-language: EN-US;"><span style="mso-list: Ignore;">-<span style="font: 7.0pt "Times New Roman";"> </span></span></span><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">final
details for the upcoming 2019 EACPT Congress </span><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">to be held in Stockholm from 29th June - 2nd July
in 2019 </span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-bottom: 12.0pt; mso-add-space: auto; mso-list: l0 level1 lfo2; text-indent: -18.0pt;">
<span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: Arial;"><span style="mso-list: Ignore;">-<span style="font: 7.0pt "Times New Roman";">
</span></span></span><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">early planning for the next EACPT
Congress, to be held in Athens in 2021, from 26<sup>th</sup> – 29<sup>th</sup>
June</span></div>
<div class="MsoListParagraphCxSpMiddle" style="margin-bottom: 12.0pt; mso-add-space: auto; mso-list: l0 level1 lfo2; text-indent: -18.0pt;">
<span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: Arial;"><span style="mso-list: Ignore;">-<span style="font: 7.0pt "Times New Roman";">
</span></span></span><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">updates from EACPT Research,
Regulatory and Education working groups</span></div>
<div class="MsoListParagraphCxSpLast" style="margin-bottom: 12.0pt; mso-add-space: auto; mso-list: l0 level1 lfo2; text-indent: -18.0pt;">
<span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: Arial;"><span style="mso-list: Ignore;">-<span style="font: 7.0pt "Times New Roman";">
</span></span></span><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">EACPT awards</span></div>
<div class="MsoNormal" style="margin-bottom: 12.0pt;">
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">The next EACPT Congress will be held from 29th June to 2nd July in 2019
in Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics. </span><br />
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"></span><br />
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"><b>Early bird registration deadline - 10th April 2019.</b> </span><a href="http://www.eacpt2019.org/registration/">Register online for the 2019
EACPT Congress in Stockholm</a></span><br />
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">
<br />
The Congress will address <b><i>Tomorrow's Healthcare Challenges</i></b> and
will be held at the City Conference Centre - 5 minutes from Stockholm Central
Station.</span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;">
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://1.bp.blogspot.com/-JlMhflf5drI/XKdY4I4XTWI/AAAAAAAACjo/_ik7rN84WcQsi2cQrDrF9qLiK2otOgLiQCLcBGAs/s1600/IMG_6616.JPG" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="1200" data-original-width="1600" height="300" src="https://1.bp.blogspot.com/-JlMhflf5drI/XKdY4I4XTWI/AAAAAAAACjo/_ik7rN84WcQsi2cQrDrF9qLiK2otOgLiQCLcBGAs/s400/IMG_6616.JPG" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><div class="MsoNormal" style="text-align: justify;">
<span style="font-size: x-small;"><b><span lang="EN-US" style="background: white none repeat scroll 0% 0%; font-family: "arial";">EACPT committee in Athens by Hippocrates statue. </span></b></span>
<br />
<div class="MsoNormal">
<span style="font-size: x-small;"><span lang="EN-US" style="background: white; font-family: "arial";">Back row: Per Ankaer, MCI (Denmark), </span><span class="MsoPageNumber"><span lang="EN-US" style="font-family: "arial";">Pierre Marquet (France),</span></span><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">
</span><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Vangelis Manolopoulos (Greece),
</span><span class="MsoPageNumber"><span lang="EN-US" style="font-family: "arial";">Markus
Zeitlinger (Austria), Janne Backman (Finland), Caroline Samer (Switzerland) Donald
Singer (UK), Michial van Agtmael
(Netherlands), Achim Schmidtko (Germany). Front row: </span></span><span class="MsoPageNumber"><span lang="FR-CH" style="font-family: "arial"; mso-ansi-language: FR-CH;">Jamie Coleman (UK), </span></span><span class="MsoPageNumber"><span lang="EN-US" style="font-family: "arial";">Tabassome Simon (France), </span></span><span class="MsoPageNumber"><span lang="FR-CH" style="font-family: "arial"; mso-ansi-language: FR-CH;">Ylva Böttiger (Sweden), </span></span><span class="MsoPageNumber"><span lang="EN-US" style="font-family: "arial";">Arantxa Sancho Lopez (Spain), Gerard Rongen (Netherlands).</span></span></span><span lang="EN-US" style="font-family: "arial"; mso-bidi-font-weight: bold;"></span></div>
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
span.MsoPageNumber
{mso-style-unhide:no;
mso-style-parent:"";
mso-ansi-language:EN-US;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style></div>
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style></td></tr>
</tbody></table>
<span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">The Congress Reception on the evening of Saturday
29th June, will be held at <a href="https://international.stockholm.se/the-city-hall/">Stockholm City Hall</a>,
the venue of the <a href="https://www.nobelprize.org/ceremonies/menus-at-the-nobel-banquet/">Nobel
Prize banquet.</a></span><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"><br />
<br />
The Keynote Opening Lecture will be given by the President at the Karolinska
Institute, Professor Ole Petter Ottersen, on global health and clinical
pharmacology.</span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;">
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Professor Urs Meyer from Switzerland will
give the <a href="http://eacpt.blogspot.com/2019/03/2017-eacpt-lifetime-achievement-award.html">2019
EACPT Lifetime Achievement Award Lecture based on his work on individual
variation in drug response.</a></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;">
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Further awards will be presented, including
Scientific Awards, including </span><span lang="EN-US" style="font-family: "arial";">Young
Investigator, and EACPT Education Awards. </span><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"><br />
<br />
Around 60 invited speakers are expected from throughout Europe and beyond.
Congress keynote lectures, sessions and themes will include:</span><span lang="EN-US" style="font-family: "arial";"></span></div>
<ul type="disc">
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Advanced therapies </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Ageing populations</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Anti-coagulation</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Anti-microbial resistance</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Beating cancer </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Chronic disease </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Clinical drug research of tomorrow</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Clinical pharmacologists versus computers </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Clinical use of pharmacokinetics</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Closing the money gap </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Computers vs. clinical pharmacologists</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Deprescribing </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Drug-drug interaction</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Drug regulation in the 2020s </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Drug utilisation</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">EACPT meets Asian
Societies </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Ethics in clinical research </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Global Health</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">How to become a clinical pharmacologist </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">How to make an oral presentation</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">How to measure drug exposure </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">How to measure drug use </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">How to perform a health economic study </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Inter-professional exchange for better drug
treatment </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Mental health</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Misuse of medicines </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Patient empowerment</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Polypharmacy: joint symposium with the <a href="http://en.kscpt.org/">Korean Society</a> (KSCPT) </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"> medicine: <a href="http://www.ephar.org/home.html">EPHAR</a>-EACPT joint
symposium</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Preparing tomorrow's prescribers </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Prescribing and deprescribing</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Publish or perish</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Rare diseases</span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Targeting small populations </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">The critically ill patient </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Treating ageing populations </span></li>
<li class="MsoNormal" style="mso-list: l1 level1 lfo1; mso-margin-bottom-alt: auto; mso-margin-top-alt: auto; tab-stops: list 36.0pt;"><span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Treating disease in children </span></li>
</ul>
<div class="MsoNormal" style="margin-bottom: 5.0pt;">
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Major awards to be presented at the Stockholm Congress include the EACPT
Lifetime Achievement Award, the biennial EACPT Scientific Award for best
publication on a clinical pharmacology or therapeutic theme, Young Investigator awards jointly with EPHAR, and the EACPT Education Award.<br />
<br />
Opportunities for EACPT Associate Members include<br />
* discounted registration fees for EACPT meetings<br />
* networking with colleagues worldwide through the global EACPT network of
Associate Members <br />
* active involvement in EACPT Working Parties and other activities<span style="color: blue;"> </span></span></div>
<div class="MsoNormal" style="margin-bottom: 5.0pt;">
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;"><a href="https://www.eacpt.eu/register/">Find out how to become an
Associate Member of the EACPT</a> </span></div>
<div class="MsoNormal" style="margin-bottom: 5.0pt;">
<span style="font-family: "arial"; mso-ansi-language: EN-GB; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-US;">Future EACPT Congresses will be held in: <br />
- 2021 Athens<br />
- 2023 Rotterdam<br />
<br />
The EACPT was founded in 1993 and now includes as members all national
organisations for clinical pharmacology in Europe, as well as organisations
from further afield internationally. The EACPT aims to provide educational and
scientific support for the more than 4000 individual professionals interested
in clinical pharmacology and therapeutics throughout the European region, with
its congresses attended by a global audience. The EACPT also advises policy
makers on how the specialty can contribute to human health and wealth.</span></div>
<div class="MsoNormal">
<br /></div>
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:"Courier New";
panose-1:2 7 3 9 2 2 5 2 4 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;
mso-font-charset:2;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;
text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-noshow:yes;
mso-style-priority:99;
color:purple;
mso-themecolor:followedhyperlink;
text-decoration:underline;
text-underline:single;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
mso-style-unhide:no;
mso-style-qformat:yes;
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:36.0pt;
mso-add-space:auto;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
{mso-style-priority:34;
mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
mso-add-space:auto;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
{mso-style-priority:34;
mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
mso-add-space:auto;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
{mso-style-priority:34;
mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-type:export-only;
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:36.0pt;
mso-add-space:auto;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:633946686;
mso-list-type:hybrid;
mso-list-template-ids:609639394 -1718189144 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
{mso-level-start-at:0;
mso-level-number-format:bullet;
mso-level-text:-;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Arial;
mso-fareast-font-family:"Times New Roman";}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1858932750;
mso-list-template-ids:850450926;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
-->
</style>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-62899630356705212252019-03-09T04:06:00.001-08:002019-03-09T04:06:59.034-08:002019 EACPT Lifetime Achievement Award to go to Professor Urs Meyer from Switzerland<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">The EACPT is
delighted to announce that the 2019 Lifetime Achievement Award of the
European Association of Clinical Pharmacology and Therapeutics will go
to Professor Urs Meyer from Switzerland.</span></span><br />
<br />
<div style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;">
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">The Award, which includes the EACPT silver medal, will be presented to Professor Meyer during the 2019 EACPT congress in Stockholm which is being held from 29 June to 2 July
2019.</span></span></div>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">To register for the congress and attend Professor Meyer's Lifetime Award Lecture click on <a class="url-ext" data-full-url="http://www.eacpt2019.org/" href="https://t.co/lwemURL2fS" rel="url noopener noreferrer" target="_blank">eacpt2019.org</a> </span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Urs A. Meyer went through a remarkable career as physician and
scientist whose discoveries and scientific results have fundamentally
contributed to clinical pharmacology and its development in recent
decades.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><a href="https://2.bp.blogspot.com/--QSag89w5pA/XIOpdeNAKxI/AAAAAAAACiI/9ieqRDEj_QIka3-P7KdwqoqNrc8oiWyJwCLcBGAs/s1600/Urs_A_Meyer_11062013-768x491.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="491" data-original-width="768" height="204" src="https://2.bp.blogspot.com/--QSag89w5pA/XIOpdeNAKxI/AAAAAAAACiI/9ieqRDEj_QIka3-P7KdwqoqNrc8oiWyJwCLcBGAs/s320/Urs_A_Meyer_11062013-768x491.jpg" width="320" /></a>His research has focused on “pharmacological individuality” or
person-to-person variation of drug response throughout his career, from
studying the drug sensitivity of the pharmacogenetic disease porphyria
to the pharmacogenomics of drug disposition and its co-regulation by drug
interactions and environmental factors. </span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">These predictable variations in
drug response are important components of individualized drug therapy
or personalized and stratified medicine. Urs Meyer probably is best
known for the discovery of the molecular mechanisms of several common
genetic polymorphisms of drug disposition. His laboratory identified the
genes and mutations in these genes causing variation in drug response
and developed the first pharmacogenetic DNA tests, initially for the
genes now called CYP2D6 and NAT2. The publications describing these
genetic variations in drug response in Nature, PNAS, Lancet, etc. are
some of the most cited papers in the therapeutic literature. </span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">At that
time they transformed the field of pharmacogenetics into a molecular
science. Urs Meyer’s group was engaged and productive in a further type of
inter-individual variation of drug response, namely the transcriptional
activation or repression of numerous genes, including many drug
metabolizing enzymes and drug transporters, by exogenous and endogenous
factors. His laboratory has discovered important early steps in the
recognition mechanisms for these factors in cells and the consequent
signal transfer to the nucleus. This is an area of great clinical
importance with regard to understanding inter-individual variations in the
therapeutic and toxic effects of drugs. </span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Urs Meyer takes care of most of the porphyria families in
Switzerland and in several surrounding countries. Focusing on the pharmacogenetic
disease porphyria and its unsolved syndrome of neuropsychiatric
symptoms Urs Meyer’s team has
developed an animal model of this pharmacogenetic disease, imitating
the human defect. These mice have a phenotype closely resembling the
human disorder and are presently used in several laboratories to develop
new therapeutic approaches to the treatment of inducible acute
porphyria.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Sustained productivity across the domains of basic and clinical pharmacology
has resulted in over 340 original publications, reviews and book
chapters. Urs Meyer has been listed since 2001 within the
exclusive ISI’s Highly Cited Researchers database. His publications have
been cited over 30,000 times and his H-index is 93.
Urs Meyer’s scientific achievements have also has been recognized by
numerous awards and honours, including the Rawls-Palmer Award for Progress
in Medicine of the American Society for Clinical Pharmacology and
Therapeutics and the RT Williams Distinguished Scientific Achievement
Award of the International Society for the Study of Xenobiotics – among
many others.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Beyond the laboratory and patient care, Urs Meyer has maintained a strong commitment to the teaching
of rational therapeutics to medical students and to training programmes
in drug development sciences, e.g. within the European Center for
Pharmaceutical Medicine ECPM courses in science-based drug development.
He has trained 71 graduate students and 62 post-doctoral fellows and more
than 35 of his previous collaborators are now in academic positions all
over the world. A number of scientists, of whom 9 from the USA, have
spent time as sabbatical professors in the laboratory of Urs Meyer.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span></span><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Urs Meyer also has assumed leadership roles at the
international level, including the WHO and NIH. He has served on
numerous peer review panels and editorial boards, presently as Associate
Editor of Annual Reviews of Pharmacology and Toxicology. He was the
inaugural Editor-in-Chief of the Journal of Personalized Medicine in
2011. As an example of his international activities, he was selected to
present the Pharmacogenomics Research Network PGRN to the NIH Council in
2000 and was a member of the External Scientific Panel for this
program. He also was president of the International Society for the
Study of Xenobiotics (ISSX) 2010-2011, with offices in Washington, D.C.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">The EACPT was founded 25 years ago and now includes
as members all national organisations for clinical pharmacology in Europe, as
well as organisations from further afield internationally. The EACPT aims to
provide educational and scientific support for the more than 4000 individual
professionals interested in clinical pharmacology and therapeutics throughout
the European region, with its congresses attended by a global audience. The
EACPT also advises policy makers on how the specialty can contribute to human
health and wealth.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">The official journal of the EACPT is the <a href="https://www.eacpt.eu/publications/eacpt-journal/">European Journal of Clinical Pharmacology</a>. </span></span>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-14960789884885939122019-02-11T15:31:00.001-08:002019-02-12T09:01:30.387-08:00Still time to submit an abstract for the EACPT Congress in Sweden: 29th June to 2nd July 2019<div dir="ltr" style="text-align: left;" trbidi="on">
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://2.bp.blogspot.com/-ub58ECXi3us/XGIHGmdixJI/AAAAAAAACho/zqtiHhdZYhckAHJNiCP8CST3R6jgehWIgCLcBGAs/s1600/EACPT_banner_Kastellholmen_Photo_Jeppe-Wikstrom_21-1320x440.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="440" data-original-width="1320" height="132" src="https://2.bp.blogspot.com/-ub58ECXi3us/XGIHGmdixJI/AAAAAAAACho/zqtiHhdZYhckAHJNiCP8CST3R6jgehWIgCLcBGAs/s400/EACPT_banner_Kastellholmen_Photo_Jeppe-Wikstrom_21-1320x440.jpg" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Stockholm</span></td></tr>
</tbody></table>
<span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">The next </span></span><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">EACPT Congress will be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology,
Clinical Pharmac</span>ology and Therapeutics. <br /><br />The Congress will address <b><i>Tomorrow's
Healthcare Challenges</i></b> and will be held at the City Conference Centre - 5
minutes from Stockholm Central Station.</span></span><br />
<br />
<a href="https://b-com.mci-group.com/AbstractSubmission/EACPT2019.aspx"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">Abstract closing date extended to 14th March.</span></span></a><br />
<br />
<div style="text-align: left;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;"><a href="http://www.eacpt2019.org/registration/">Register online </a></span></span></span></div>
<div class="MsoNormal" style="text-align: left;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><br /></span>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span lang="EN-US">The Congress Reception on the evening of Saturday 29th June, will be held at <a data-mce-href="https://international.stockholm.se/the-city-hall/" href="https://international.stockholm.se/the-city-hall/">Stockholm City Hall</a>, the venue of the <a data-mce-href="https://www.nobelprize.org/ceremonies/menus-at-the-nobel-banquet/" href="https://www.nobelprize.org/ceremonies/menus-at-the-nobel-banquet/">Nobel Prize banquet.</a></span></span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">The
Keynote Opening Lecture will be given by the President at the
Karolinska Institute, Professor Ole Petter Ottersen, on global health
and clinical pharmacology.</span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;">Around 60 invited speakers are expected
from throughout Europe and beyond. Congress keynote lectures, sessions
and themes will include:</span><br />
<ul><span style="font-family: "arial" , "helvetica" , sans-serif;">
</span>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Advanced
therapi</span>es </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Chronic
disease </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Clinical
pharmacologists versus computers </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Closing the
money gap </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Drug
regulation in the 2020's </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">EACPT meets
Asian Societies </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">EPHAR-EACPT
joint symposium on personalised medicine </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Ethics in
clinical research </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">
Global Health</span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to become
a clinical pharmacologist </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to measure
drug exposure </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to measure
drug use </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to perform
a health economic study </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Interprofessional
exchange for better drug treatment </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Misuse of
medicines </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Patient
empowerment</span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Preparing
tomorrow's prescribers </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Prescribing
and deprescribing</span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Targeting
small populations </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">The critically
ill patient </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Treating
ageing populations </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Treating
cancer </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Treating
children </span></span></li>
</ul>
</div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-size: small;"><span style="font-family: "arial";">Major </span></span><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">awards to be presented at the Stockholm Congress include the EACPT Lifetime Achievement Award and the biennial EACPT Scientific Award for best publication on a clinical pharmacology or therapeutic theme.</span></span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;"><br />
Opportunities for EACPT Associate Members include<br />
* discounted registration fees for EACPT meetings<br />
* networking with colleagues worldwide through the global EACPT network of
Associate Members <br />
* active involvement in EACPT Working Parties and other activities<span style="color: blue;"> </span></span></span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;"><a href="https://www.eacpt.eu/register/"><span style="color: blue;">Find
out how to become an Associate Member of the EACPT</span></a> </span></span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">Future EACPT Congresses will be held in: <br />
- 2021 Athens<br />
- 2023 Rotterdam<br />
<br />
The EACPT was founded in 1993 and now includes as members all
national organisations for clinical pharmacology in Europe, as well as
organisations from further afield internationally. The EACPT aims to provide
educational and scientific support for the more than 4000 individual
professionals interested in clinical pharmacology and therapeutics throughout
the European region, with its congresses attended by a global audience. The
EACPT also advises policy makers on how the specialty can contribute to human
health and wealth.</span></span></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><br /></span></span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-38008729944504178032018-09-06T06:20:00.003-07:002018-09-07T06:34:17.064-07:00Updates on the EACPT from the UK<br />
<div class="MsoNormal">
<span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">The EACPT Executive Committee is meeting in early September
2018 in Birmingham in the UK West Midlands to plan for future activities. This
coincides with the latest <a href="https://www.birmingham.ac.uk/facilities/mds-cpd/conferences/eacpt-2018/index.aspx">EACPT
Focus meeting: Innovations in CPT Education</a> - which is being held at the <a href="https://www.birmingham.ac.uk/facilities/mds-cpd/conferences/eacpt-2018/index.aspx">University
of Birmingham from 7-8 September 2018</a>. Delegates for the Focus meeting are
expected from a wide range of countries, including Finland, Germany, Ireland, The
Netherlands, Sweden, Switzerland, Lithuania, Poland, Italy, Spain, Romania,
Malta and the UK.</span></div>
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
a:link, span.MsoHyperlink
{mso-style-noshow:yes;
mso-style-priority:99;
color:blue;
text-decoration:underline;
text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-noshow:yes;
mso-style-priority:99;
color:purple;
mso-themecolor:followedhyperlink;
text-decoration:underline;
text-underline:single;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style><br />
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://4.bp.blogspot.com/-8lihll2cW94/W5Grv_LaIxI/AAAAAAAACfA/cxVpi-OH-Nw27q3P2VE0aWn1sHRiVXCigCLcBGAs/s1600/Bham%2B6.9.18.JPG" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="1056" data-original-width="1600" height="211" src="https://4.bp.blogspot.com/-8lihll2cW94/W5Grv_LaIxI/AAAAAAAACfA/cxVpi-OH-Nw27q3P2VE0aWn1sHRiVXCigCLcBGAs/s320/Bham%2B6.9.18.JPG" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "arial" , "helvetica" , sans-serif; font-size: small;"><span style="font-family: "arial"; font-size: x-small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">EACPT EC in Birmingham</span></span></span></td></tr>
</tbody></table>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">Key matters for discussion by the EACPT EC included:</span></span></span><br />
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;"><span style="font-family: "arial" , "helvetica" , sans-serif;">1. Future EACPT Congresses - the next is due to be held from 29th June to 2nd July in 2019 in Stockholm as
a partnership between the EACPT and the Swedish Society for Pharmacology,
Clinical Pharmac</span>ology and Therapeutics. The Congress will address <b><i>Tomorrow's
Healthcare Challenges</i></b> and will be held at the City Conference Centre - 5
minutes from Stockholm Central Station.</span></span><br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.</span></span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">Congress sessions and themes will include:</span></span><br />
<ul>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Advanced
therapies </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Chronic
disease </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Clinical
pharmacologists versus computers </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Closing the
money gap </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Drug
regulation in the 2020's </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">EACPT meets
Asian Societies </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">EPHAR-EACPT
joint symposium on personalised medicine </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Ethics in
clinical research </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">
Global Health</span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to become
a clinical pharmacologist </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to measure
drug exposure </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to measure
drug use </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">How to perform
a health economic study </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Interprofessional
exchange for better drug treatment </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Misuse of
medicines </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Patient
empowerment</span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Preparing
tomorrow's prescribers </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Prescribing
and deprescribing</span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Targeting
small populations </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">The critically
ill patient </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Treating
ageing populations </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Treating
cancer </span></span></li>
<li><span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;">Treating
children </span></span></li>
</ul>
</div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">2. New EACPT Awards for Best Scientific Paper in the previous 12 months on a clinical pharmacology or therapeutics theme. Authors may be from any discipline and do not have to be members of the EACPT. These
awards will be launched in September 2018 and awarded initially every 2 months
(6 times a year) from November 2018. </span></span><br />
<br />
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">Award winners will receive a free one year
Individual Associate Membership (IAM) of the EACPT. Winners who are already
EACPT IAMs will receive a 100€ prize. Papers which receive an EACPT Scientific
Paper Award will be eligible to be considered for the biennial <a href="https://www.eacpt.eu/category/scientific-awards/"><span style="color: blue;">EACPT Scientific Award</span></a>.<br /><br />
3. <a href="https://www.eacpt.eu/"><span style="color: blue;">EACPT working
groups</span></a> on Education, Research, Young Professionals, and Regulation
and Ethics.<br /><br />
4. New EACPT web series on Meet the Clinical Pharmacologists<br /><br />
5. Opportunities from links with international organisations such as the
European Medicines Agency, IUPHAR, EPHAR and UEM|<br /><br />
6. Opportunities for Individual Associate Members including:<br />
* discounted registration fees for EACPT meetings<br />
* networking with colleagues worldwide through the global EACPT network of
Associate Members <br />
* active involvement in EACPT Working Parties and other activities<span style="color: blue;"> </span></span></span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;"><a href="https://www.eacpt.eu/register/"><span style="color: blue;">Find
out how to become an Associate Member of the EACPT</span></a> </span></span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">The EACPT Executive Committee meets 6 monthly, with regular additional
discussions by teleconference on key EACPT strategy and activities.</span></span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-family: "arial"; font-size: small;">Future EACPT Congresses will be held in: <br />
- 2019 Stockholm<br />
- 2021 Athens<br />
- 2023 Rotterdam<br />
<br />
The EACPT was founded in 1993 - 25 years ago - and now includes as members all
national organisations for clinical pharmacology in Europe, as well as
organisations from further afield internationally. The EACPT aims to provide
educational and scientific support for the more than 4000 individual
professionals interested in clinical pharmacology and therapeutics throughout
the European region, with its congresses attended by a global audience. The
EACPT also advises policy makers on how the specialty can contribute to human
health and wealth.</span></span></div>
<span style="font-family: "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><br /></span></span>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-69745410195420143712018-04-17T03:03:00.000-07:002018-04-17T06:48:26.368-07:00Updates on digital media and health at the European Medicines Agency<div dir="ltr" style="text-align: left;" trbidi="on">
<span style="font-family: "arial"; font-size: 12.0pt; font-weight: normal;">
</span><br />
<h1>
<span style="font-family: "arial"; font-size: 12.0pt; font-weight: normal;">Safe and effective healthcare matters for
society as a whole.</span></h1>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://1.bp.blogspot.com/-_F_m-U5s--c/WtXkeGGtUGI/AAAAAAAACdQ/k1dAdK1QxOsrdBh1cm529nf5PlMQwkLygCLcBGAs/s1600/IMG_5853.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="303" data-original-width="490" height="197" src="https://1.bp.blogspot.com/-_F_m-U5s--c/WtXkeGGtUGI/AAAAAAAACdQ/k1dAdK1QxOsrdBh1cm529nf5PlMQwkLygCLcBGAs/s320/IMG_5853.jpg" width="320" /></a></div>
<span style="font-family: "arial"; font-size: 12.0pt; font-weight: normal;"><style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:Times;
panose-1:2 0 5 0 0 0 0 0 0 0;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:3 0 0 0 1 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
h1
{mso-style-priority:9;
mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
mso-pagination:widow-orphan;
mso-outline-level:1;
font-size:24.0pt;
font-family:Times;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-unhide:no;
mso-style-locked:yes;
mso-style-link:"Heading 1";
mso-ansi-font-size:24.0pt;
mso-bidi-font-size:24.0pt;
font-family:Times;
mso-ascii-font-family:Times;
mso-hansi-font-family:Times;
mso-font-kerning:18.0pt;
mso-ansi-language:EN-GB;
mso-fareast-language:EN-US;
font-weight:bold;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style>Digital media
and health is the key theme of the latest joint meeting of the European
Medicines Agency (EMA) Human Scientific Committees' Working Parties with
Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’
Organisations (HCPWP) being held in London on 17<sup>th</sup> and 18<sup>th</sup>
April 2018. Digital media and health topics are being discussed, including
recent learning and trends with regard to mHealth, social media, real-word
evidence and electronic <span class="glossary-term">product information</span>.</span><br />
<br />
<div class="MsoNormal">
<span lang="EN-US" style="font-family: "arial";">Katja Neubauer
from the European Commission opened the session with an update on EU
initiatives with regard to digital health. She considered 3 priority areas on
digitizing health and care: access of the citizen to his or her data for
example in electronic medical records and electronic prescribing; access to big
data to improve health policy and regulatory decisions; and using digital
health make policy decisions more patient-centred. </span></div>
<div class="MsoNormal">
<span lang="EN-US" style="font-family: "arial";">She discussed
clinical use studies, including development of European Reference rare diseases,
applying digital health to anticipating epidemics and EU-wide infectious
threats and applying Real World Data in medicines development.<br /><br />An EC report on
Digital Single Market strategy is due to be published on 25<sup>th</sup> April.</span></div>
<div class="MsoNormal">
<span lang="EN-US" style="font-family: "arial";">Hans-Georg
Eichler from the EMA went on to discuss the relevance of real world evidence to
regulation of medicines, including understanding efficacy and monitoring for
unexpected risk and for long-term risk. In particular, he considered use of real
world evidence to match the speed of science progress with timely integration
of innovations into clinical practice. </span></div>
<div class="MsoNormal">
<span lang="EN-US" style="font-family: "arial";">He considered case
studies on accelerating drug development, contrasting findings from real world
evidence with those from classical randomized clinical trials; applying real
world evidence to monitoring potential long term adverse effects of medicines –
for example from risks of insertional mutagenesis following gene therapy for
thalassaemia which needs surveillance for decades; and applying real world
evidence to understanding therapeutic complexity – for example deciphering
combinatorial complexity in oncology treatment with regard to differences in
therapeutic impact from treatment order, dose and washout duration between
treatments.<br /><br />He also discussed
applying learning for health care from other sectors (aviation, automotive …), including
data-driven innovation from rapid feedback loops.</span></div>
<div class="MsoNormal">
<span lang="EN-US" style="font-family: "arial";">Alison Cave from
the EMA discussed key points from recent workshops hosted by the Agency. She
stressed the need for a common data model for Europe. A key theme arising from
discussion of EMA registries had been the need for common core data elements,
checks on data quality (consistency, accuracy and completeness), long-term
curation, availability and governance.<br /><br />Jane Mosely
discussed how real-world evidence and patient registries can be used to support
early access to medicines, risk-benefit analysis and provide rapid replication
within different populations of initial findings. She noted that there are
currently limited requests for data from real-world evidence to support pre-authorisation
decisions and post-authorisation questions about safety and efficacy. Some aspects
which need to be considered include eligibility of participants, outcome definition,
patient safety, and extrapolation of findings throughout the EU</span>.</div>
<div class="MsoNormal">
<br />
<span lang="EN-US" style="font-family: "arial";">Alexios Skarlatos
(EMA) and </span><span class="st"><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">Dr. </span></span><i><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">C</span></i><i><span lang="EN-US" style="font-family: "arial"; font-style: normal;">ésar Hernández García</span></i><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "arial";"> </span></i><span lang="EN-US" style="font-family: "arial";">(Spanish Agency of Medicines and Medical
Devices) discussed Electronic Product Information. Steps include consultation
on revising Patient Leaflet content and adding agreed new content, including
targeted messages for relevant subgroups of patients. There are already case
studies from the Netherlands (Watchyourmeds), quick guides for patients in Norway
and in Spain structured product information accessible e.g. by scanned quick response (QR) codes.
International standards are needed and transition to a Digital first model. <span style="mso-spacerun: yes;"> </span>There will be a European Commission-EMA-HMA multistakeholder
workshop on the use of electronic Summary of medical Product Characteristics (SmPC)/Patient
Leaflets (PL) on 28<sup>th</sup> – 29<sup>th</sup> November 2018</span>.<br />
<br />
<span lang="EN-US" style="font-family: "arial";">Further speakers
will discuss from health professional, regulator, patient, consumer perspectives
Real World Evidence (Kieran Breen, Patient Representative on the EMA Committee for Advanced Therapies),
mHealth (Kathi Apostolidis, European Cancer Patient Coalition) and Social Media
(Caroline Morton, </span><span lang="EN-US" style="font-family: "arial"; mso-fareast-font-family: "Times New Roman";">International Bureau for Epilepsy</span><span lang="EN-US" style="font-family: "arial";">).</span></div>
<div class="MsoNormal">
<span lang="EN-US" style="font-family: "arial";">More about the
meeting and the presentations can be found on the <a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2018/04/event_detail_001629.jsp&mid=WC0b01ac058004d5c3">EMA
website.</a></span></div>
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:Times;
panose-1:2 0 5 0 0 0 0 0 0 0;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:3 0 0 0 1 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
h1
{mso-style-priority:9;
mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
mso-pagination:widow-orphan;
mso-outline-level:1;
font-size:24.0pt;
font-family:Times;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
mso-themecolor:hyperlink;
text-decoration:underline;
text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-noshow:yes;
mso-style-priority:99;
color:purple;
mso-themecolor:followedhyperlink;
text-decoration:underline;
text-underline:single;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-unhide:no;
mso-style-locked:yes;
mso-style-link:"Heading 1";
mso-ansi-font-size:24.0pt;
mso-bidi-font-size:24.0pt;
font-family:Times;
mso-ascii-font-family:Times;
mso-hansi-font-family:Times;
mso-font-kerning:18.0pt;
mso-ansi-language:EN-GB;
mso-fareast-language:EN-US;
font-weight:bold;}
span.glossary-term
{mso-style-name:glossary-term;
mso-style-unhide:no;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-30487553381989218472018-04-05T09:26:00.002-07:002018-04-06T08:08:00.626-07:00EACPT - 2018 Updates from Stockholm<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://4.bp.blogspot.com/-uHMwrQNr3e4/Wsd8h8rWTsI/AAAAAAAACc0/2c-oKUrMHmEOE4oX3GZGJ4FBCO_OT7kTwCLcBGAs/s1600/IMG_7538_preview%255B1%255D.jpeg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="563" data-original-width="904" height="199" src="https://4.bp.blogspot.com/-uHMwrQNr3e4/Wsd8h8rWTsI/AAAAAAAACc0/2c-oKUrMHmEOE4oX3GZGJ4FBCO_OT7kTwCLcBGAs/s320/IMG_7538_preview%255B1%255D.jpeg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "arial" , "helvetica" , sans-serif;">EACPT Executive Committee meeting in Stockholm</span></td></tr>
</tbody></table>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial"; font-size: 11.0pt;">The EACPT Executive Committee is meeting in early April 2018 in
Stockholm to plan for future activities.<br style="mso-special-character: line-break;" />
</span><span style="display: none; font-family: "arial"; font-size: 11.0pt;"></span></div>
<span style="font-family: "arial"; font-size: 11.0pt;">Key matters for discussion include</span><br />
<span style="font-family: "arial"; font-size: 11.0pt;"></span><br />
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial"; font-size: 11.0pt;">
1. Future EACPT Congresses - the next is due to be held in 2019 in Stockholm as
a partnership between the EACPT and the Swedish Society for Pharmacology,
Clinical Pharmacology and Therapeutics. The Congress will address <i>Tomorrow's
Healthcare Challenges</i> and will be held at the City Conference Centre - 5
minutes from Stockholm Central Station.<br />
2. The next <a href="https://www.birmingham.ac.uk/facilities/mds-cpd/conferences/eacpt-2018/index.aspx">EACPT Focus meeting: Innovations in CPT Education</a> - to be held at
the <a href="https://www.birmingham.ac.uk/facilities/mds-cpd/conferences/eacpt-2018/index.aspx">University of Birmingham 7-8 September 2018</a>.<br />
3. New EACPT Awards for Best Scientific Paper in the previous 12 months. These
awards will be launched on 1st June 2018 and awarded initially every 2 months
(6 times a year) from August 2018. Award winners will receive a free one year
Individual Associate Membership (IAM) of the EACPT. Winners who are already
EACPT IAMs will receive a 100€ prize. Papers which receive a EACPT Scientific
Paper Award will be eligible to be considered for the biennial <a href="https://www.eacpt.eu/category/scientific-awards/"><span style="color: blue;">EACPT Scientific Award</span></a>.<br />
4. <a href="https://www.eacpt.eu/"><span style="color: blue;">EACPT working
groups</span></a> on Education, Research, Young Professionals, and Regulation
and Ethics.<br />
5. New EACPT web series on Meet the Clinical Pharmacologists<br />
6. Opportunities from links with international organisations such as the
European Medicines Agency, IUPHAR, EPHAR and UEM<br />
7. Opportunities for Individual Associate Members including:<br />
* discounted registration fees for EACPT meetings<br />
* online access to the official EACPT Journal - Clinical Therapeutics <br />
* networking with colleagues worldwide through the global EACPT network of
Associate Members <br />
* active involvement in EACPT Working Parties and other activities<span style="color: blue;"> </span></span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial"; font-size: 11.0pt;"><a href="https://www.eacpt.eu/register/"><span style="color: blue;">Find
out how to become an Associate Member of the EACPT</span></a> </span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial"; font-size: 11.0pt;">The EACPT Executive Committee meets 6 monthly, with regular additional
discussions by teleconference on key EACPT strategy and activities.</span></div>
<div class="MsoNormal" style="mso-margin-bottom-alt: auto; mso-margin-top-alt: auto;">
<span style="font-family: "arial"; font-size: 11.0pt;">Future EACPT Congresses will be held in: <br />
- 2019 Stockholm<br />
- 2021 Athens<br />
- 2023 Rotterdam<br />
<br />
The EACPT was founded in 1993 - 25 years ago - and now includes as members all
national organisations for clinical pharmacology in Europe, as well as
organisations from further afield internationally. The EACPT aims to provide
educational and scientific support for the more than 4000 individual
professionals interested in clinical pharmacology and therapeutics throughout
the European region, with its congresses attended by a global audience. The
EACPT also advises policy makers on how the specialty can contribute to human
health and wealth.</span></div>
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-72385795998138047722017-12-12T10:46:00.001-08:002017-12-12T11:02:11.005-08:00Developing a Common Health Data Model for Europe<div dir="ltr" style="text-align: left;" trbidi="on">
<span style="font-size: small;">
</span><style><font size="3">
<!--
/* Font Definitions */
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:Times;
panose-1:2 0 5 0 0 0 0 0 0 0;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:3 0 0 0 1 0;}
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:1 134676480 16 0 131072 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
a:link, span.MsoHyperlink
{mso-style-noshow:yes;
mso-style-priority:99;
color:blue;
text-decoration:underline;
text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-noshow:yes;
mso-style-priority:99;
color:purple;
mso-themecolor:followedhyperlink;
text-decoration:underline;
text-underline:single;}
p
{mso-style-noshow:yes;
mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:Times;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-bidi-font-family:"Times New Roman";}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</font></style><span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">The European Medicines
Agency has been holding a 2 day international workshop in London [11th -12th
December 2017] to define opportunities and challenges for a common health
data model in Europe. The expected outcome of the workshop was agreeing guiding
principles for the development of such a Common Data Model (CDM) in Europe,
including key criteria for validation in the context of regulatory
decision-making.<br />
<br />
<a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2017/10/event_detail_001524.jsp&mid=WC0b01ac058004d5c3" target="_blank">See more about the workshop</a></span></span><br />
<span style="font-size: small;"><span style="font-family: Arial;"> </span></span><br />
<span style="font-size: small;">
</span><div class="separator" style="clear: both; text-align: center;">
<span style="font-size: small;"><a href="https://4.bp.blogspot.com/-JzocRAHZhFw/WjAnkfS1FUI/AAAAAAAACWk/wq93S_m6fKINMNgbW1fUkyxUOOlyt73hQCLcBGAs/s1600/IMG_2631%2B%25283%2529.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="924" data-original-width="1600" height="115" src="https://4.bp.blogspot.com/-JzocRAHZhFw/WjAnkfS1FUI/AAAAAAAACWk/wq93S_m6fKINMNgbW1fUkyxUOOlyt73hQCLcBGAs/s200/IMG_2631%2B%25283%2529.jpg" width="200" /></a></span></div>
<span style="font-size: small;"><a href="https://4.bp.blogspot.com/-NlaPZ6YnnHI/Wi_dyElGHtI/AAAAAAAAFLk/y4FWQzXdLO8uX_itVo3fOjEdPl_ZguqmQCLcBGAs/s1600/IMG_2631%2B%282%29.jpg"><span lang="EN-US" style="font-family: Arial; text-decoration: none;"></span></a><span style="font-family: Arial;">A common data model could help harmonise healthcare data
across multiple data sets and provide a mechanism to conduct pan-European
studies in a timely manner to address regulatory questions. At the same time,
applying a common model to European data has multiple challenges. The meeting
brought together regulators with academia, data holders and the pharmaceutical
industry.</span></span><br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;"><br />Sessions included talks from
experts from North America and the European region discussing lessons learned
and current challenges in very large current clinical data resources,
regulatory verification and related issues. Common data model case
studies included <a href="https://www.sentinelinitiative.org/" target="_blank">Sentinel</a> – the Harvard-based FDA
system for accessing patient data from health data partners across the USA and <a href="https://www.cnodes.ca/" target="_blank">CNODES</a>
(the Canadian Network for Operational Drug Effect Studies) which can access
data on 100 million patients – a similar scale to Sentinel.</span></span><br />
<br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">The U.S. Food and Drug
Administration's (FDA) <a href="https://www.fda.gov/Safety/FDAsSentinelInitiative/ucm2007250.htm" target="_blank">Sentinel Initiative</a> uses a common
health data model to improve the FDA’s ability to identify safety issues for
medical products. Sentinel actively surveys pre-existing electronic healthcare
data from multiple sources.</span></span><br />
<br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">Themes at the workshop
included ensuring the relevance of CDMs to health policy, keeping timelines
short, inter-operability, consent and related ethical issues, and careful
internal and external validation of clinical definitions, data, software and
analytical models.</span></span><br />
<br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">From the perspective of
health professionals, policy makers, regulators and the public, key future
questions include whether clinical outcomes from common data models will be
generalisable or only relevant to specific sub-populations based on geography,
genetics, demographics and/or complex co-morbidity. In the era of
precision medicine there is the clear need is to avoid “right” answers from the
wrong clinical populations and “wrong” answers from the right populations.</span></span><br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">Further key points to
consider include the cost of CDMs and who should pay; and whether updating
existing databases will be sufficient or will new, more robust databases be
needed.</span></span><br />
<br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;"> Future <a href="https://www.eacpt.eu/">EACPT</a> Congresses will be held in: </span></span><br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">- 2019 Stockholm </span></span><br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">- 2021 Athens </span></span><br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">- 2023 Rotterdam</span></span><br />
<br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;">The EACPT was founded in
1993 - 24 years ago - and now includes as members all major national
organisations for clinical pharmacology in Europe, as well as organisations
from further afield internationally. The EACPT aims to provide educational and
scientific support for the more than 4000 individual professionals interested
in clinical pharmacology and therapeutics throughout the European region, with
its congresses attended by a global audience. The EACPT also advises policy
makers on how the specialty can contribute to human health and wealth.</span></span><br />
<br />
<span style="font-size: small;">
</span><span style="font-size: small;"><span style="font-family: Arial;"><a href="http://www.clinicaltherapeutics.com/">Clinical Therapeutics</a>, the
Official Journal of EACPT</span></span><br />
<span style="font-size: small;">
</span><br />
<span style="font-size: small;">
</span><div class="MsoNormal">
<br /></div>
<span style="font-size: small;">
</span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-25991749517429137252017-11-22T07:01:00.001-08:002017-11-22T07:02:53.650-08:00European Medicines Agency to move from London to Amsterdam<div dir="ltr" style="text-align: left;" trbidi="on">
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">After a final round dead-heat vote by member states on Monday 20th November, following the drawing of lots, Amsterdam
has been confirmed as the new home for the European Medicines Agency. On
current plans, the EMA will be operating in Amsterdam from April 2019.</span></span><br />
<span style="font-size: small;"><br /></span>
<br />
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><span style="font-size: small;"><a href="https://2.bp.blogspot.com/-iy7HCdKh6kE/WhWLg9CzJQI/AAAAAAAAFHg/-Gpum4QtrIcNh2U9FzKx2RocWPeCswf9wCLcBGAs/s1600/IMG_2462.jpg" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="410" data-original-width="1600" height="100" src="https://2.bp.blogspot.com/-iy7HCdKh6kE/WhWLg9CzJQI/AAAAAAAAFHg/-Gpum4QtrIcNh2U9FzKx2RocWPeCswf9wCLcBGAs/s400/IMG_2462.jpg" width="400" /></a></span></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span style="font-size: xx-small;">The EMA's Patients and Consumers Working Party annual meeting</span></span></span></td></tr>
</tbody></table>
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">Meantime
the EMA's Patients and Consumers Working Party (PCWP) is holding its
annual meeting with all EMA eligible patient/consumer consumer
organisations to consider relocation preparedness, patient and consumer
involvement in EMA activities, highlights from major EMA committees and
updates on pharmacovigilance, information on medicines and future work
programmes in 2018 and 2019 for the PCWP and the EMA's Healthcare
Professionals Working Party.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">The European Medicines Agency is concerned
with regulation of medicines and
other advanced therapies for humans and animals for 28 countries across the European Union.</span></span><br />
<span style="font-size: small;"><br /></span>
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">
</span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">The EMA has established mechanisms for involving patients in regulatory
assessment: patients’ value perception and value systems. The EMA also has an increasing remit to engage with stakeholder
organisations and to improve transparency in its activities for the ~510 million
citizens of the European Union.</span><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"> </span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">Furthermore the EMA has a major role in educating patients, carers and health care
professionals about medicines. </span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"> </span></span><br />
<span style="font-size: small;"><br /></span>
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">There
remain many decisions and actions for the coming months needed to
ensure the smooth relocation of the EMA to Amsterdam and either to
develop systems to retain UK expertise for the EMA or replace that
expertise.</span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"> </span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">For the EMA, these include</span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">: </span></span><br />
<ul style="text-align: left;">
<li><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">maximising staff retention </span></span></li>
<li><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">maintaining capacity to continue the work of the EMA </span></span></li>
<li><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">continuing productive engagement with stakeholder groups: patients, carers,
healthcare professionals ...</span></span></li>
<li><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">maintaining the capacity of the EMA to engage with the public </span></span></li>
</ul>
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">
</span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">
</span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">For
the UK, there are pressing questions regarding the future regulation of
medicines in the UK post-Brexit, the impact of loss of international
influence of UK regulators and other experts on medicines and the impact
of loss of biotech and pharmaceutical companies from London to
Amsterdam.</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"></span></span></span></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-46465344210749511822017-11-10T06:50:00.000-08:002017-11-11T02:25:13.228-08:00EACPT 2017 Updates from Vienna<style>
<!--
/* Font Definitions */
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
{mso-style-priority:99;
mso-style-link:"Plain Text Char";
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.5pt;
font-family:Courier;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
span.PlainTextChar
{mso-style-name:"Plain Text Char";
mso-style-priority:99;
mso-style-unhide:no;
mso-style-locked:yes;
mso-style-link:"Plain Text";
mso-ansi-font-size:10.5pt;
mso-bidi-font-size:10.5pt;
font-family:Courier;
mso-ascii-font-family:Courier;
mso-hansi-font-family:Courier;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:595.0pt 842.0pt;
margin:72.0pt 45.45pt 72.0pt 45.45pt;
mso-header-margin:35.4pt;
mso-footer-margin:35.4pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style>
<br />
<div class="MsoPlainText">
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://4.bp.blogspot.com/-WTA0tii4fIQ/WgXBukycxII/AAAAAAAACWA/udejmKn-ti0rrgM7OZkSk4dCSGl4Y_mmACLcBGAs/s1600/IMG_1968.JPG" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="1600" data-original-width="1200" height="320" src="https://4.bp.blogspot.com/-WTA0tii4fIQ/WgXBukycxII/AAAAAAAACWA/udejmKn-ti0rrgM7OZkSk4dCSGl4Y_mmACLcBGAs/s320/IMG_1968.JPG" width="240" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><b>Votive Church, Vienna</b></span></td></tr>
</tbody></table>
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">The EACPT Executive Committee is meeting in Vienna from 10th - 11th
November to plan for future activities.</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">Key matters for discussion include</span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;"> </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">1. Future EACPT Congresses - the next is due to be held in 2019 in
Stockholm as a partnership between the EACPT and the Swedish Society for
Pharmacology, Clinical Pharmacology and Therapeutics. The Congress will address <i>Tomorrow's Healthcare Challenges</i> and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">2. <a href="https://www.eacpt.eu/">EACPT working groups</a> on Education, Research, Young Professionals,
and Regulation and Ethics.</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">3. Opportunities from links with
international organisations such as the European Medicines Agency, IUPHAR,
EPHAR and UEMS </span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">4. Opportunities for Individual Associate Members including: </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">* discounted registration fees for EACPT meetings</span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">* online access to the official EACPT Journal - Clinical Therapeutics </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">* networking with colleagues worldwide through the global EACPT
network of Associate Members </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">* active involvement in EACPT Working Parties and other activities</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;"><a href="https://www.eacpt.eu/register/">Find out how to become an Associate Member of the EACPT</a> </span></div>
<div class="MsoPlainText">
<br /></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://2.bp.blogspot.com/-wYeE9dssgk0/WgW1JQEGilI/AAAAAAAACV0/8v0FuSMIGvwbEDaNQGtSzJc1-91AYCJMwCEwYBhgL/s1600/r2%2BEACPT%2BEC%2BVienna%2B2.jpg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="670" data-original-width="1600" height="268" src="https://2.bp.blogspot.com/-wYeE9dssgk0/WgW1JQEGilI/AAAAAAAACV0/8v0FuSMIGvwbEDaNQGtSzJc1-91AYCJMwCEwYBhgL/s640/r2%2BEACPT%2BEC%2BVienna%2B2.jpg" width="640" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><style>
<!--
/* Font Definitions */
@font-face
{font-family:"MS 明朝";
mso-font-charset:78;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1791491579 18 0 131231 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Cambria;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073743103 0 0 415 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:10.0pt;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
{mso-style-priority:99;
mso-style-link:"Plain Text Char";
margin:0cm;
margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.5pt;
font-family:Courier;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
span.PlainTextChar
{mso-style-name:"Plain Text Char";
mso-style-priority:99;
mso-style-unhide:no;
mso-style-locked:yes;
mso-style-link:"Plain Text";
mso-ansi-font-size:10.5pt;
mso-bidi-font-size:10.5pt;
font-family:Courier;
mso-ascii-font-family:Courier;
mso-hansi-font-family:Courier;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"MS 明朝";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-US;
mso-fareast-language:JA;}
.MsoPapDefault
{mso-style-type:export-only;
margin-bottom:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 90.0pt 72.0pt 90.0pt;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
-->
</style>
<br />
<div class="MsoPlainText" style="text-align: left;">
<span lang="EN-US" style="font-family: "helvetica";"><b>Back row</b>:
Caroline Samer, Switzerland; Donald Singer, UK; Michiel van Agtmael,
Netherlands; Ylva Böttiger, Sweden; Jamie Coleman, UK; Pierre Marquet, France;
Emilio Clemente, Italy; Markus Zeitlinger, Austria.</span></div>
<div class="MsoPlainText" style="text-align: left;">
<span lang="EN-US" style="font-family: "helvetica";"><b>Front row</b>:
Janne Backman, Finland; Jolanta Gulbinovi</span><span lang="EN-US" style="font-family: "helvetica"; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman";">č</span><span lang="EN-US" style="font-family: "helvetica";">, Lithuania; Arantxa Sancho López, Spain; Achim
Schmidtko, Germany.</span></div>
</td></tr>
</tbody></table>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">The EACPT Executive Committee meets 6 monthly, with regular interim
discussions by teleconference on key EACPT strategy and activities.</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;"> Future EACPT Congresses will be held in: </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">- 2019 Stockholm </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">- 2021 Athens </span></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">- 2023 Rotterdam</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;">The EACPT was founded in 1993 - 24 years ago - and now includes as
members all national organisations for clinical pharmacology in Europe, as well
as organisations from further afield internationally. The EACPT aims to provide
educational and scientific support for the more than 4000 individual professionals
interested in clinical pharmacology and therapeutics throughout the European
region, with its congresses attended by a global audience. The EACPT also
advises policy makers on how the specialty can contribute to human health and
wealth.</span></div>
<div class="MsoPlainText">
<br /></div>
<div class="MsoPlainText">
<span lang="EN-US" style="font-family: "helvetica"; font-size: 12.0pt;"><a href="http://www.clinicaltherapeutics.com/">Clinical Therapeutics</a>, the Official Journal of EACPT</span></div>
<div class="MsoPlainText">
<br /></div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-43403796747320238242017-11-10T06:28:00.000-08:002017-11-10T06:28:15.052-08:00The 2017 EACPT Scientific Award<span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span lang="EN-US" style="color: #1a1a1a;"><span lang="EN-US">The <a href="http://www.eacpt2017.org/">EACPT 2017 Congress</a> was held in
Prague from 24th-27th June with 566 participants from all 5 continents - 28%
from beyond the European Region, from Australia to China, Japan and South Korea
to the USA.</span><span lang="EN-US"> The Congress included 22 sessions with
Keynote Lectures on current issues for research, education and clinical
practice on safe and effective use of medicines. Almost 500 oral and poster
presentations will be presented by delegates from the European Region and
around the world.</span></span></span></span></span></span><div class="MsoNormal" style="margin-bottom: 0cm;">
<div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<br /></div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: left; margin-right: 1em; text-align: left;"><tbody>
<tr><td style="text-align: center;"><a href="https://3.bp.blogspot.com/-evkY5sFmymE/WVOTS6eTggI/AAAAAAAACP0/gP_qUPGawGkg0jU94_5xav392HWVAecUwCLcBGAs/s1600/D%2BWebb.jpg" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="750" data-original-width="1334" height="220" src="https://3.bp.blogspot.com/-evkY5sFmymE/WVOTS6eTggI/AAAAAAAACP0/gP_qUPGawGkg0jU94_5xav392HWVAecUwCLcBGAs/s400/D%2BWebb.jpg" width="400" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-size: x-small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">Prof. Simon, Prof Webb and Prof. </span></span><span style="font-size: x-small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span class="st">Böttiger</span></span></span></span></span></td></tr>
</tbody></table>
<div class="MsoNormal" style="margin-bottom: 0.0001pt;">
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span lang="EN-US" style="color: #1a1a1a;"><span lang="EN-US">The
EACPT Scientific Award was presented to Professor David Webb, President
of the British Pharmacological Society for his 2015 Lancet paper on
PATHWAY 2. This study</span></span></span></span></span><span style="font-size: small;"><br /></span>
<span style="font-size: small;"><span lang="EN-US" style="color: #1a1a1a; font-family: "helvetica neue";">reported a significant improvement in blood pressure control in older,
overweight patients with poorly controlled hypertension despite combination
medical therapy when the mineralocorticoid antagonist spironolactone was added,
treatment supported by directly observed therapy.</span></span></div>
</div>
<div class="MsoNormal" style="margin-bottom: 0cm;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 0cm;">
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span lang="EN-US">Future EACPT Congresses</span></span></span><br />
<span style="font-size: small;">
</span>
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span lang="EN-US">- 2019
Stockholm <br />- 2021 Athens <br />- 2023 Rotterdam</span></span></span></div>
<span style="font-size: small;">
<span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">
</span><br />
</span><br />
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span lang="EN-US">The EACPT was founded in 1993 and
now includes as members all national organisations for clinical pharmacology in
Europe, as well as organisations from further afield internationally. The EACPT
aims to provide educational and scientific support for the more than 4000
individual professionals interested in clinical pharmacology and therapeutics
throughout the European region, with its congresses attended by a global
audience. The EACPT also advises policy makers on how the specialty can
contribute to human health and wealth.</span></span></span></div>
<span style="font-size: small;">
<span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">
</span><br />
</span><br />
<div class="MsoPlainText">
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span lang="EN-US"><a href="http://www.clinicaltherapeutics.com/">Clinical Therapeutics</a>, the Official Journal
of EACPT. </span></span></span></div>
</div>
EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0tag:blogger.com,1999:blog-6469238689184049840.post-34366142477954090652017-09-19T01:53:00.001-07:002017-09-20T08:12:49.845-07:00Global threat of antibiotic resistance<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://3.bp.blogspot.com/-G7g24-PT9FY/WcDWxY7bPfI/AAAAAAAACTo/ADTK9xqtXAYl8LGIq-8LIBuOzf_40E2NACLcBGAs/s1600/WHO%2BAMR.png" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="862" data-original-width="1485" height="185" src="https://3.bp.blogspot.com/-G7g24-PT9FY/WcDWxY7bPfI/AAAAAAAACTo/ADTK9xqtXAYl8LGIq-8LIBuOzf_40E2NACLcBGAs/s320/WHO%2BAMR.png" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">WHO estimates of impact on mortality from AMR</span></td></tr>
</tbody></table>
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">The European Medicines agency, in partnership with the ECDC (<a href="https://ecdc.europa.eu/en">European Centre for Disease Prevention and Control</a>), is holding a <a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2017/09/event_detail_001506.jsp&mid=WC0b01ac058004d5c3">workshop on global challenges from antimicrobial resistance</a> (AMR). </span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">There are 3 major current approaches to tackling AMR: </span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">1. reducing selection pressure on microbes to reduce the chance of their developing AMR. This needs strategies to reduce overuse of antimicrobial medicines. </span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">2. reducing human/human and animal/human transmission microbes. This needs effective infection control measures</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">3. increasing the availability of new antibiotics through more R & D combined with limiting their use within evidence-based guidelines - ie effective antibiotic stewardship.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">There needs to be an integrated approach combining a pipeline of effective new antimicrobial and careful stewardship of existing antimicrobials through their effective use. However from a recent international survey, 20% of the public who took part were unaware that overuse of antibiotics leads to antimicrobial resistance to treatment. Furthermore 44% were unaware that antibiotics are ineffective against colds and 'flu'. </span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">The WHO has estimated that, without major global action, by 2050 there may be ~400,000 preventable deaths annualy in the European region alone, as a result of lack of effective antiobiotics for serious infections.</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">Martial Plantady from the European Commission opened the day by discussing the EU Action plan launched in 2011 and running until 2016 against the threats from antimicrobial resistance. He noted that many solutions were described within the plan however there remain major challenges to effective implementation of the Plan, including:</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- widespread and worldwide antibiotic use for growth promotion in livestock</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- resulting need to push strategy to ban antibiotic use in livestock beyond the EU</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- availability of animal and human data across member states</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- effective surveillance on appropriate and prudent use of antimicrobials in humans</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">Some solutions include </span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- effective dissemination of guidelines on prudent use of antibiotics in animals and humans</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- Antibiotic Awareness Days</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- more effective coordination of R & D across industry and academic sectors on new antimicrobials, alternatives, vaccines and rapid diagnostic tests</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- engagement with key health professional and patient stakeholder organisations</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">The new EU Action Plan on antibiotic resistance was published in June 2017, with 3 pillars supported by strengthened measures for infection prevention and control:</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- making the EU Region a best practice region on AMR</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- improving research and innovation</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">- shaping the global agenda on AMR</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">At the 68th World Health Assembly in May 2015, the World Health
Assembly endorsed a <a href="http://www.who.int/antimicrobial-resistance/global-action-plan/en/">global action plan</a> to tackle antimicrobial
resistance, including antibiotic resistance, the most urgent drug
resistance trend. Carmen Pessoa da Silva from the WHO underlined the key point that if AMR remains unresolved, the global threat would be enormous both for human health as well as for the world economy. She summarised 5 key elements of WHO strategy against AMR.</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">1. improved awareness and understanding (annual WHO awareness week)</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">2. strengthen knowledge through surveillance and research 9WHO Global AMR Surveillance System - GLASS - further report due in Jan 2018 - 47 countries are fully enrolled - 25% of member states)</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">3. reduce incidence of infection</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">4. optimise use of anti-microbial medicines</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">5. ensure sustainable investment for R & D</span></span><br />
<br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">The </span></span><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><a href="http://www.pgeu.eu/en/">Pharmaceutical Group of the European Union</a> </span></span>represents the ~400,000 community pharmacists who dispense medicines for the ~500 million population of the European Union. Around 46 million people visit a community pharmacist every day in Europe.</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;">James Wilkinson discussed efforts of the PGEU to educate community pharmacists and the public in rational use of antimicrobial medicines.</span></span><br />
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><br /></span></span>
<span style="font-size: small;"><span style="font-family: "helvetica neue" , "arial" , "helvetica" , sans-serif;"><br /></span></span>EACPT updateshttp://www.blogger.com/profile/07191345501970172344noreply@blogger.com0